key: cord-0034075-s8s6psx2
authors: nan
title: Jahrestagung 2011 der Österreichischen Gesellschaft für Pneumologie
date: 2011
journal: Wien Klin Wochenschr
DOI: 10.1007/s00508-011-0050-8
sha: 57ce149fd9f7d83e6ca376ec682d675ca9e133b6
doc_id: 34075
cord_uid: s8s6psx2

nan

Wir präsentieren den Fall einer 53-jährigen Patientin, welche im Februar 2011 aufgrund im Th orax-CT detektierter bilateraler Raumforderungen (rechter OL, linker UL) an unserer Abteilung aufgenommen wurde. Davor litt sie seit November des Vorjahres an einem unteren Atemwegsinfekt und Globusgefühl, später seien dann auch Hämotysen hinzugekommen.

Die Berufs-bzw. Sozialanamnese verbleibt unauff ällig, aktiver Nikotinabusus bestand nie, 10 Jahre war sie einer Passivrauchbelastung ausgesetzt.

Im Routinelabor fi nden sich außer einer erhöhten BSG keinerlei Auff älligkeiten, an Tumormarkern im Serum lediglich das CA19-9 geringfügig erhöht.

Es folgt die Bronchoskopie zu Histologiegewinnung, wobei die feingewebliche Aufarbeitung der gewonnenen Proben ein Pleomorphes Karzinom bestehend aus einem Adenokarzinomanteil und einem spindelzelligen Karzinom ergibt. Der Adenokarzinomanteil ist aufgrund des Markerprofi ls einem Adenokarzinom vom enterischen Typ zuzuordnen. Das pleomorphe Karzinom der Lunge gehört in die Gruppe der sarkomatoiden Karzinome und ist charakterisiert durch eine sehr schlechte Prognose.

Diese Kombination ist äußerst ungewöhnlich, wenn nicht -auch nach Einschätzung eines renommierten Referenzpathologen -bisher gar einzigartig.

Husten und Belastungsdyspnoe bei einem älteren Patienten W. Auer¹, H. Reiher¹, R. Einspieler², T. Keck³, V. Stepan¹ ¹Abteilung für Innere Medizin, Krankenhaus der Elisabethinen, Graz, Österreich ²Institut für Radiologie, Krankenhaus der Elisabethinen, Graz, Österreich ³Abteilung für Hals-Nasen-Ohren-Heilkunde, Krankenhaus der Elisabethinen, Graz, Österreich Husten und Belastungsdyspnoe bei älteren Patienten sind häufi ge Zuweisungsdiagnosen an Lungenfachärzte. Die entsprechenden Ursachen fi nden sich jedoch nicht immer allein im kardiopulmonalen Bereich.

Ein 77-jähriger Patient wurde aufgrund zunehmender Belastungsdyspnoe und Hustenattacken zur weiterführenden Abklärung zugewiesen. Die phasenweise produktiven Hustenanfälle traten teils zeitlich mit der Nahrungsaufnahme zusammenhängend auf. Zusätzlich bestanden zehn Kilogramm Gewichtsverlust innerhalb des vorhergehenden Jahres.

Es präsentierte sich ein adipöser Patient mit arrhythmischer Herzaktion und mäßigen Beinödemen beidseits.

Die kardialen Untersuchungen zeigten eine de-novo Vorhoffl immerarrhythmie, eine Herzinsuffi zienz mit einer echokardiographisch gemessenen Ejektionsfraktion von 45 % und eine schlecht kontrollierte arterielle Hypertonie.

Die pulmonale Abklärung ergab tagsüber ausgeglichene Blutgase und eine mittelgradige kombinierte Ventilationsstörung mit Betonung der kleinen Atemwege. Ursächlich hierfür waren radiologisch darstellbare postentzündiche Lungenveränderungen sowie die Herzinsuffi zienz. Die Schlafuntersuchung zeigte eine zentral-periodische Schlafatemstörung mit gutem Ansprechen auf nächtliche Sauerstoffgabe.

Das Schluckaktröntgen ergab eine Raumforderung dorsal des Hypopharynx mit gestörtem Kontrastmittelabfl uss. Eine HNO-ärztliche Untersuchung bestätigte eine Vorwölbung im Larynx. Die Hals-Computertomographie zeigte bis zwei Zentimeter große, den Hypopharynx und den Larynx dorsal imprimierende Spondylophyten als Ursache für die Schluckstörung.

In Zusammenschau der Befunde hatten die Beschwerden unterschiedliche Gründe. Ursächlich für die Belastungsdyspnoe war die kardiale Problematik. Kausal für den Husten waren -durch hochgradige degenerative Halswirbelsäulenveränderungen bedingte -Schluckstörungen, welche zu rezidivierenden Aspirationen führten.

Der Patient wurde neurochirurgisch vorgestellt, lehnte jedoch eine angebotene operative Abtragung der Spondylophyten ab. Es erfolgten eine kardiale Rekompensation, die Adaptierung der antihypertensiven Th erapie sowie das Einleiten einer oralen Antikoagulation. Eine nächtliche Sauerstoff therapie wurde verordnet.

Dieser Fall zeigt, dass besonders bei multimorbiden Patienten zeitgleich auftretende Symptome verschiedenste Ursachen haben können. Umso wichtiger erscheint hier eine interdisziplinäre Abklärung mit besonderer Berücksichtigung fachfremder Diff erentialdiagnosen.

Weiters soll das Augenmerk auf ein in der pneumologischen Fachliteratur unterrepräsentiertes Krankheitsbild gerichtet werden. Degenerative Veränderungen der Halswirbelsäule können eine Vielzahl respiratorischer Probleme bedingen, sind jedoch fast ausschließlich Th ema HNO-ärztlicher oder orthopädischer Publikationen.

Zwei Wochen später musste die Patientin wegen akuter Verschlechterung und respiratorischer Globalinsuffi zienz (pO2: 45 mmHg, pCO2: 58 mmHg, pH: 7,18) an unserer Intensivstation aufgenommen und intubiert werden. Nativradiologisch zeigte sich eine Zunahme der beidseitigen intrapulmonalen Konsolidierungsherde, sodass eine breite antibiotische Th erapie etabliert wurde. Die Histologie der Lingula-und Unterlappen-Biopsate, die mittels Videoassistierter Th orakoskopie (VATS) gewonnen wurde, ergab eine abszedierende nekrotisierende Pleuropneumonie mit intravasalen Th rombenbildungen. Aufgrund des Verteilungsmuster der pulmonalen Abszedierungen und des Th rombennachweises wurde unter Annahme eines septisch-embolischen Geschehens eine transösophagale Echokardiographie (TEE) durchgeführt. Diese zeigte eine an der Trikuspitalklappe fl otierende kugelige Struktur kompatibel mit Trikuspitalendokarditis und ursächlich für die septisch-pyämischen Lungenabszesse. Im Bronchialsekret wurde Pseudomonas aeroginosa kultiviert, mehrfach wiederholte Blutkulturen blieben negativ. Bei Verdacht auf Pseudomonas-Endokarditis wurde die antibiotische Th erapie entsprechend modifi ziert. Dennoch kam es primär zu einer Verschlechterung mit nachfolgendem septischen Kreislaufversagen, welches jedoch intensivmedizinisch beherrscht werden konnte. Mit Besserung der Klinik kam es auch radiologisch zur Regredienz der beidseitigen pulmonalen Infi ltrate, die Echokardiographie zeigte eine Besserung. Der Intensivaufenthalt wurde in weiterer Folge durch eine Critical-illness Neuro-bzw. Myopathie sowie durch einen septischembolisch bedingten beidseitigen Sehverlust, wobei das rechte Auge erblindete, kompliziert. Wegen prolongiertem Weaning musste die Patientin tracheotomiert und zunächst an unserer Respiratory Care Unit (RCU) vom Respirator entwöhnt, und schließlich mit 2 Liter Sauerstoffi nsuffl ation auf unsere Normalstation übernommen werden. Nach 3 Monaten konnte die Patientin Rollator-mobil mit 2 Liter Langzeitsauerstoff therapie an ein Rehabilitationszentrum transferiert werden.

Im 3-monatigen Verlauf zeigte die Computertomographie des Th orax eine deutliche Regredienz der beidseitigen pulmonalen Veränderungen, die Echokardiographiekontrolle war zu diesem Zeitpunkt unauff ällig. Als Zufallsbefund fand sich -bioptisch verifi ziert -ein gastrointestinaler Stromatumor (GIST) des Magens. Nachdem es sich histologisch um keinen invasiv wachsenden Tumor handelte, stellte dies primär keine Kontraindikation zur Transplantation dar.

In Folge zeigten sich im Th orax-CT neben bekannten Granulomen (PPD und Quantiferon negativ, Sputum ZN negativ) neue, dringend sekundärblastomsuspekte bis zu 8 mm große Rundherde.

In einer PET-Untersuchung ließ sich ein ausgedehnter hypermetaboler Herd im Oberbauch links -dem Primum an der kleinen abstracts ÖGP Jahrestagung 2011 wkw 17-18/2011 © Springer-Verlag A7 ÖGP Wir berichten über eine 25-jährige Patientin aus dem Kosovo. Klinik: Seit 2 Wochen Glieder,-Gelenks,-und Kopfschmerzen; Fieber bis 38 Grad; Gewichtsabnahme von 2, 3 kg im letzten Monat; kein Husten.

Zur Diagnose bei radiologischem V.a. Tbc wird neben den Standardmethoden (Mikroskopie, NAT + Kultur aus Sputum und BAL) bei pos. IGRA aus dem Blut die Tb-Spot-Untersuchung aus der BAL durchgeführt. Durch diese Methode, welche zur Diagnose der aktiven Tbc in Niederprävalenzländer geeignet erscheint, gelingt eine frühzeitige Erhärtung des Verdachts, welcher nach 21 Tagen mit dem Eintreff en der positiven Flüssigkultur (Mycobacterium tuberculosis Komplex) bestätigt wird. In der Folge ist auch die Festkultur positiv (Mycobacterium tuberculosis Komplex). Der Mycobacterium tuberculosis Komplex ist sensibel auf die gängige antituberkulöse Th erapie. Eine 49-jährige Patientin wurde aufgrund rezidivierender sinubronchialer Infekte und dem radiologischen Verdacht einer interstitiellen Lungenerkrankung an unsere Abteilung zugewiesen.

Anamnese: Bei der Patientin waren seit einem Jahr wiederholt Infekte der oberen und unteren Atemwege aufgetreten, die mehrfach antibiotisch behandelt wurden. Es waren keine internen Vorerkrankungen erhebbar, sie war Nichtraucherin, Penicillinallergie war bekannt.

Klinik und Befunde: Der klinische Status war unauff ällig. Im Labor fi el einzig eine minimale Hypoproteinämie (Totalprotein 6,2 g/ dl) auf, welche laut Patientin schon aus früheren Routine-Laborkontrollen bekannt war. Lungenfunktionell bestand keine Einschränkung.

Radiologie: Das Th orax-CT zeigte teils dichte, teils milchglasartige Strukturalterationen in beiden Unterlappen, im Mittellappen und der Lingula, sowohl subpleural als auch zentral gelegen. Zudem bestanden Bronchiektasien im Untergeschoß. Auff allend waren weiters vergrößerte hiläre und mediastinale Lymphknoten sowie eine Splenomegalie.

Bronchoskopie: Zur weiteren Abklärung wurde eine Bronchoskopie mit Biopsien und einer bronchoalveolären Lavage (BAL) durchgeführt. Die Histologie zeigte Lymphozytenaggregate im Interstitium, fi brös verbreiterte Alveolarsepten und ein Epitheloidzellgranulom ohne Nekrose. Die BAL ergab ein lymphozytäres Bild (Lymphozyten 38 %, CD4/CD8-Ratio 5,4). In der Immunphänotypisierung war keine Klonalität nachweisbar, somit konnte ein Lymphom ausgeschlossen werden.

Insgesamt sprach dieses Bild für eine lymphozytäre interstitielle Pneumonie (LIP).

Die häufi gsten Ursachen einer LIP sind HIV, Dysproteinämien, Autoimmunerkrankungen (Sjögren-Syndrom, RA, SLE) und Virusinfekte (v.a. EBV).

Bei During the 2009 H1N1 infl uenza A virus pandemic, some patients developed severe pneumonia leading to acute respiratory distress syndrome(ARDS). Several studies described the need of intensive care or ECMO support in these mostly young and healthy patients.

We report the case of bilateral lung transplantation (LUTX) in a 29 year old female bridged with ECMO due to ARDS after combined infection of H1N1 and respiratory syncytial virus (RSV). Th e patient was admitted to the hospital with infl uenza symptoms extending over several weeks. H1N1 testing was positive at admission. Th e disease followed a rapidly progressive course requiring mechanical ventilation and aggressive medical treatment. However, the respiratory situation worsened increasingly and the virological examination revealed a secondary infection with RSV. Ultimately the patient needed ECMO support. Blood cultures were negative at all time. After 10 days on ECMO no improvement of the clinical situation occurred and therefore the patient was transferred to our center for LUTX. At the time of listing, tests for H1N1 and RSV were already negative. A bilateral, size reduced (middle-lobe and lingual resection) LUTX on central ECMO was performed. Ischemic time on the right side was 295 min and In drei konsekutiven Sputumkulturen zeigte sich jedoch nach 4 Wochen ein Wachstum atypischer Mykobakterien. Die molekularbiologische Speziesidentifi zierung mittels Gensonde (GenoType Mycobacterium AS, Hain Lifesciences) ergab M. szulgai.

Entsprechend der Resistenzbestimmung (Löwenstein-Jensen-Medium) wurde schließlich die eingeleitete Th erapie wie folgt adaptiert: Rifampicin (300 mg), Ethambutol (500 mg), Clarythromycin (500 mg). Diese sollte für mindestens 12 Monate fortgeführt werden. Regelmäßige Kontrollen der Patientin zeigten erfreulicherweise eine deutliche klinische Besserung. Radiografi sch konnte bei einer 2-Monats-Kontrolle jedoch noch keine wesentliche Befundänderung erkannt werden.

Ein Holländer in Salzburg -Lunge, Lacke und Snowboards 

Multiple intrapulmonale Infi ltrate und Hämoptysen nach Entbindung U. Radda 1 , T. Jaritz 1 , H. Martinz², E. Isak³, C. Geltner 1 375 min on the left side. 1200 ml of erythrocyte-concentrates,140 ml of thrombocyte-concentrates and 2000 ml of fresh-frozen-plasma were needed. Th e ECMO could be removed at the end of the LUTX. Th e patient received a standard immunosuppressive therapy with cortisone,tacrolimus and mycophenalate. For infection prophylaxis intravenous administration of tazobactam, ganciclovir, cmv-antibodies and caspofungin was used in combination with amphotericin-b and gentamicin for inhalation. Th e patient left the ICU on the 24th postoperative day and could be discharged from the hospital 2 weeks later. Th e patient is now 3 months post LUTX and no recurrence of the viral infection has occurred so far.

Th is report demonstrates a fulminate course of a viral infection in a before healthy patient. LUTX in such critically ill patients is an option if virological tests are negative and a single organ failure is present. Laborchemisch auff ällig waren Hb 8,9 g/dl, Th rombozyten 448 g/l, CRP 12,4 mg/l (Grenzwert 5 mg/l).

Eine Computertomographie des Schädels war unauff ällig. Im Th oraxröntgen fi el eine Verschattung im linken Mittel-und Unterfeld auf (Abb. 1).

Computertomographisch fand sich eine Raumforderung nahezu den gesamten linken Unterlappen einnehmend mit Atelektase (Abb. 2).

Es folgte eine CT-gezielte Punktion, histologisch wurde spindelzelliges Tumorgewebe -suspekte Anteile eines sarkomatoiden Mesothelioms -beschrieben.

Klinisch auff ällig waren rezidivierende Hypoglykämien (Glucose bei Aufnahme 126 mg/dl, HbA1c 4,9 %), die kontinuierliche Glucoseinfusionen erforderten.

Zur weiteren Abklärung bei thorakalem Neoplasma wurde der Patient an unsere Fachabteilung transferiert. Ein schmaler linksseitiger Pleuraerguss erwies sich als Transsudat, das zytologische Bild war unspezifi sch.

Endobronchial war der linke Unterlappen subtotal duch Kompression von außen stenosiert, die Zytologie zeigte unklare atypische Zellverbände, die Histologie eine fi brosierende Bronchitis.

C-Peptid war erniedrigt und Seruminsulin im unteren Normbereich.

Mit der Arbeitsdiagnose rezidivierender paraneoplastischer Hypoglykämien bei Pleuratumor erfolgte eine linksseitige Pneumonektomie. Histologisch konnte das Vorliegen eines fi brösen Pleuratumors bestätigt werden.

Postoperativ bestand ein normaler Glucose-Stoff wechsel. Lokalisierte fi bröse Pleuratumoren sind eine seltene, häufi g asymptomatische Erkrankung (1 Klinik und Befunde: Bis auf polyzystische Veränderungen mit einer Zystengröße zwischen 5 und 25 mm war das Lungenparenchym im Th orax-CT weitgehend unauff ällig, lungenfunktionell bestätigte sich die anamnestisch angegebene COPD Grad III.

Klinisch auff ällig war ein Schmetterlings-Erythem im Gesicht. Serologisch fanden sich deutlich erhöhte ANA mit erhöhten Subsets passend zu einem Lupus Erythematodes (LE):

• ANA 1/5120 (Fluoreszenzmuster homogen, Chromosomen positiv) • Anti-ds-DNA -Antikörper 169,4 I.E./ml Verlauf: Da bronchoskopisch bereits auswärts keine Diagnosesicherung erreicht werden konnte, entschieden wir uns für eine VATS. Es erfolgte eine atypische Segmentresektion im linken UL, histologisch zeigte sich eine lymphoide interstitielle Pneumonie (LIP), als Nebenbefund eine fokale DIP-Reaktion. Somit konnte ein systemischer Lupus erythematodes mit positiver Autoimmunserologie, Z. n. Pericarditis, monatlich auftretenden Arthralgien und einem Schmetterlingserythem gesichert werden. Die pulmonale Manifestation bestand in Form einer lymphoiden interstitiellen Pneumonie (LIP), woraus sich die Indikation zu einer Th erapie mit Endoxan und Cortison ergab. Nach 6 Zyklen zeigten sich Lungenfunktionsparameter (VCmax und FEV1) gebessert, CT-morphologisch war keine wesentliche Veränderung eingetreten.

Take home: Eine Lungenbeteiligung bei LE äußert sich typischerweise in Form von -meist beidseits basal auftretenden -pulmonalen Infi ltraten mit/ohne Hämorrhagie, Pleuritis. Die akute Lupuspneumonie ist ein seltenes Krankheitsbild, dem histologisch eine -unspezifi sche-generalisierte Vasculitis und Alveolitis zugrunde liegt, die Alveolitis ist in der BAL in der Regel lymphozytär. Ein pathognomonisches histologisches Bild ist nicht beschrieben. Die LIP als pulmonale Manifestation eines LE ist als Rarität in der Literatur beschrieben (1), im vorliegenden Fall wurde die Grunderkrankung über den "Umweg" der pulmonalen Abklärung erst aufgedeckt. Das histologische Ergebnis dieser und die mikrobiologische Aufarbeitung der Blutkulturen ergaben eine unerwartete Diagnose: Nokardiose pulmonal und invasiv (Blutkultur positiv).

Eine Th erapie mit Lidaprim forte zeigte in den folgenden Verlaufskontrollen einen sehr guten Erfolg.

Unter Immunsuppression ist nicht jeder zerfallende Lungenprozess eine Pilzpneumonie

Pneumologische Abteilung, Krankenhaus der Elisabethinen, Linz, Österreich

Bei einem Patienten, der primär aufgrund eines Pyoderma gangränosums in dermatologischer Behandlung immunsupprimiert wurde, kam es zum Auftreten eines einschmelzenden Lungenprozesses im rechten Lungenunterlappen mit bilateralen großnodulären abstracts ÖGP Jahrestagung 2011 wkw 17-18/2011 © Springer-Verlag A13 ÖGP mum therapy were screened from three outpatient heart failure clinics in Vienna. Eligible patients underwent full-night polysomnography, lung function measurements, arterial blood gas analysis, and assessment of subjective sleep quality and sleepiness.

Results: 73 patients with heart failure and stable disease underwent polysomnography. Th ree patients were excluded due to airways obstruction on lung function, leaving 70 patients (95%) for fi nal analysis (50 male, 20 female, age 64 ± 11 yrs, BMI 29 ± 5 kg/sqm). Th e overall prevalence of SDB was 79% (n = 55) with an apnea-hypopnea-index of 22 ± 18/hour of sleep. 53% of the sample had obstructive sleep apnea, 23% Cheyne-Stokes-Respiration, 3% mixed sleep apnea, and 21% patients had no evidence of SDB. Patients with SDB and those without did not diff er with respect to age, body-mass-index, cardiac function, or pharmacological treatment. Patients with SDB scored signifi cantly higher on sleepiness and sleep quality scores than heart failure patients without SDB. Patients with Cheyne-Stokes-Respiration had signifi cantly lower arterial pCO2 levels compared with the other groups.

Conclusions: Th ere is a high prevalence of sleep disordered breathing in patients with stable chronic heart failure. Th e latter fi ndings may have important diagnostic and therapeutic implications.

Incidence of solid de-novo malignoma and posttransplant lymphoproliferative disorder (PTLD) after lung transplantation -experience in Vienna Background: A factor limiting the survival after lung transplantation is de-novo malignancy. Th e immunosuppressive treatment, the increasing long-time survival and the capacity to reactivate viruses like Epstein-Barr virus (EBV) with cancer-causing potential are serious risk factors for the development of malignancies in lung transplant recipients. Th e aim of this study was to determine the incidence and outcome of patients suff ering from de-novo solid tumors and PTLD in a single center cohort.

Methods: Between 1989 and 2009 962 patients underwent lung transplantation at the lung transplant center in Vienna/Austria. 50 patients (5.2%) developed a solid tumor or PTLD. All data were collected and retrospectively analysed.

Results: 19 (38%) patients were female, 31 (62%) were male. At the time of incidence patients were on average 51 ± 15.9 years [13-73] old. 16 (32%) patients suff ered from PTLD, 10 (20%) from lung cancer, 12 (24%) from tumors of the gastrointestinal tract respectively 7 (14%) of the urinary tract. 2 female patients (4%) were detected with breast cancer, 3 patients (6%) with other neoplasms. Overall survival after solid malignoma and PTLD was 53% at 1 year, 32% at 3 years and 29% at 5 years. Th e median time to cancer appearance was collectively 1378 ± 1272 days after transplantation . 14 patients with denovo malignoma or PTLD underwent surgery, 14 were treated with chemotherapy and 4 with radiation. 3 patients were treated with chemotherapy and radiation, 2 additional with surgery. 5 patients received no therapy. Th e therapy modalities of 7 patients were unknown. Th e underlying illness, the status of Cytomegalie-Virus infection, the Objectives: We hypothesized diff erences in cardiovascular autonomic control and baroreceptor function between patients with stable chronic heart failure and Cheyne-Stokes-Respiration (CHF-CSR) and heart failure patients with obstructive sleep apnea (CHF-OSA).

Methods: We studied 14 patients with polysomnographically diagnosed CHF-CSR and 14 age, body-mass-index, and apnea-hypopnea index (AHI) matched patients with CHF-OSA. Cardiovascular autonomic tone was recorded using power spectral analysis of R-R interval variability on the morning after polysomnography. Th e slope of the regression line between beat-to-beat spontaneous systolic blood pressure and pulse interval changes was taken as an index of the sensitivity of arterial barorefl ex modulation.

Results: Th e two groups did not diff er with respect to left ventricular ejection fraction, pharmacologic treatment, or etiology of heart failure. Mean AHI was 33 14/hr in patients with CHF-CSR and 25 15/ hr in patients with CHF-OSA (p > 0.05). Patients with CHF-CSR had signifi cantly higher sympathetically mediated low frequency R-R interval variability (58 16 vs 29 15% normalized units, p < 0.01) and higher low-to-high frequency ratio of R-R interval variability (2.0 1.8 vs. 0.5 0.4, p < 0.01) than patients with CHF-OSA. Consistent with these fi ndings, mean slope of spontaneous baroreceptor activity was significantly lower in patients with CHF-CSR than in CHF-OSA (8.3 3.3 vs 35.6 24.5, p = 0.01).

Conclusions: We observed signifi cant diff erences in both sympathetic activity and baroreceptor sensitivity between patients with CHF-CSR and CHF-OSA despite similar cardiac function impairment and sleep parameters. Background: Sleep disordered breathing (SDB) in patients with chronic heart failure is associated with increased morbidity and mortality. Th e prevalence of SDB in Austrian patients with chronic heart failure, however, remains unknown.

Objectives: Multi-centre study to assess both prevalence and characteristics of SDB in an Austrian patient sample.

Methods: Patients with stable chronic heart failure (NYHA class II-IV) and left ventricular ejection fraction below 35% despite maxi-Background: In Poland, the overwhelming majority of individuals with alpha-1-antitrypsin (AAT) defi ciency still remains undiagnosed. We estimated the AAT gene frequency and prevalence in a large cohort of Polish chronic lung or liver disease patients eligible for AAT testing.

Methods: Blood samples were collected prospectively from 500 respiratory patients (COPD, emphysema, bronchiectasis, asthma). AAT serum concentration was measured by turbidimetry and PI-phenotype identifi ed by isoelectrofocusing. Th e PI*S and PI*Z alleles were confi rmed by real-time PCR; rare phenotypes were characterized by sequencing.

Results: 63 (12.6%) lung disease patients demonstrated AAT deficiency phenotypes. Calculated frequencies expressed per 1000 were for PI*Z 46.6 (95% CI: 32.3-60.8), PI*S 20,3 (95% CI: 10.8-29.8). Th e AAT gene prevalence calculated by Hardy-Weinberg equilibrium were: 1/1.16 for MM, 1/26 for MS, 1/2429 for SS, 1/11 for MZ, 1/530 for SZ and 1/462 for ZZ.

Conclusions: Our results show relatively high frequency of AAT defi ciency among Polish patients with chronic obstructive respiratory form of immunosuppression (Tacrolimus or Cyclosporin A) and the induction (with antithymocyte globulin -ATG) had no infl uence on the incidence of malignoma after lung transplantation. Th e only risk factors which could be identifi ed were the age at time of transplantation (p = 0.005) and sex (p < 0.05).

Conclusions: Immunosuppressant induced neoplasms and PTLD are an important cause of mortality. Attention needs to be payed on identifying solid de-novo malignoma and PTLD early in lung transplant recipients to achieve an advantageous outcome.

The presence of an acute phase response -refl ected by systemic infl ammatory parameters -predicts poor survival in patients with malignant pleural mesothelioma: a retrospective multicenter analysis Methods: Accordingly, a retrospective multicenter analysis of 173 pathologically proven MPM patients was performed. Clinical data including routine SIP levels, and treatment modalities were collected by the three participating institutions (Department of Th oracic Surgery, Medical University of Vienna, Department of Pulmonology, Landesklinik Hochegg and National Koranyi Institute of Pulmonology, Budapest, Hungary) and correlated with patients overall survival.

Results: Patients with elevated CRP (≥1 mg/dl), leukocytosis (>10.0 g/l), hypoalbuminaemia (<34 g/l) and high (more than 75% of leukocytes are neutrophiles) percentage of neutrophil granulocytes (PNG) had a signifi cant shorter overall survival when compared to patients with normal SIP levels (log rank tests: CRP: p < 0.001, leukocytosis: p < 0.001, hypoalbuminaemia: p = 0.008, PNG: p = 0.001). After multivariate analyses, CRP (p = 0.003) and hypoalbuminaemia (p = 0.015) remained as independent MPM outcome predictors.

Conclusions: Following these results, we propose the presence of an APR -refl ected by altered CRP and albumin levels -to be prognostic in MPM patients.

Six-minute walk test in diagnosis of COPD patients ÖGP Notch signalling plays a key role in the development of the immune system. Recently, Notch was found to confer antigen presenting cell function on mast cells, induce lung allergic responsiveness in CD4 + T-cells and regulate migration and survival of eosinophils. As basophils play a key role in allergic reactions our aim was to analyse, whether basophils express Notch-1 or Notch-2 and whether the Notch signaling pathway has an impact on basophil function.

Human basophils were isolated from venous blood of healthy donors via magnetic cell sorting (MACS®). RNA of basophils and PBMC was extracted by trizol and transcribed into cDNA using superscript III (Invitrogen®). Notch-1 and Notch-2 expression was determined by RT-PCR. To explore the functionality of Notch, basophil migration towards fMLP [10 -8 M] was evaluated in Boyden chambers. After preincubation with the specifi c gamma secretase inhibitor DAPT [10 -6 -10 -12 M], basophils migrated towards fMLP [10 -8 M] for 90 min. Th e cellulose nitrate fi lters were then dehydrated, fi xed and stained and migration depth was analysed by microscopy. Furthermore, basophils were stimulated with plate-bound Jagged-1 for 24 h before histamine release was measured by ELISA.

Th e RT-PCR revealed basophils to express both, Notch-1 and the Notch-2. In comparison to PBMC, human basophils were found to express Notch-1 to a greater extent, whereas Notch-2 expression was lower than in PBMC. With regards to the functionality of Notch signalling in human basophils we found that the gamma secretase inhibitor DAPT [10 -6 to 10 -8 M] most signifi cantly blocked basophil migration towards fMLP [10 -8 M] (p < 0.0001). Furthermore, after Jagged-1 stimulation an increase of histamine concentration by 8.67 fold could be determined.

We could show for the fi rst time that human basophils express Notch-1 and Notch-2 and that the Jagged-1/Notch signalling pathway is involved in basophil functions such as histamine release and cell migration.

The indirect Fick method is an unfeasible method for hemodynamic assessment in pulmonary arterial hypertension patients Background: Th e aim of the present retrospective study was to evaluate the suitability of hemodynamic parameters assessed by the indirect Fick method in patients suff ering from pulmonary arterial hypertension (PAH) and controls.

Methods: For this purpose right heart catheterization was performed in 42 patients (mean-age 61.2 ± 12.7 years, 29 females) with PAH and 9 controls in supine position. 60.5% of the patients revealed the diagnosis of an idiopathic PAH (n = 26), 27.9% suff ered from PAH associated with connective tissue diseases (n = 12) and the remaining 9.5% were distributed to drugs and toxins induced PAH (n = 3) and PAH associated with portal hypertension (n = 1). Hemodynamic results obtained by the indirect Fick method were compared to data obtained by the thermodilution method.

Results: Patients and controls did not diff er in age, BSA and heart rate. Th e mean cardiac output (CO) determined by the indirect Fick method (CO Fick ) in PAH patients and control population was 4.4 ± 1.8 and 4.7 ± 1.2 L/min, respectively. CO obtained by the thermodilution method (COTh ermo ) in PAH patients was consistently higher than CO Fick disorders. Estimated frequency for PI*Z and PI*S allele in respiratory group was about four-fold higher than estimated prevalence in healthy Polish population.

The effect of endothelin-1 on calcium signalling in human basophils Th e proinfl ammatory peptide endothelin-1 (ET-1) proved to be elevated in patients suff ering from asthma. As the impact of ET-1 on basophils, which numbers correlate with asthma severity, has yet to be fully understood, our aim was to map the signalling pathway of ET-1 in human basophils.

Human basophils were isolated from peripheral blood by Magnetic Cell Sorting (MACS). For RT-PCR and Western Blot analysis, RNA and protein were isolated by Trizol. Histamine release was measured via ELISA and cell migration was analysed in Boyden Chambers. To show the calcium signalling of ET-1 in human basophils, cells were loaded with fura 2-AM and monitored by fl uorescence microscopy during stimulation with ET-1 compared to fMLP [10 -8 M], ATP [10 -4 M] and ionomycin [10 -6 M] that served as controls. To discriminate between ETAR and ETBR signalling the specifi c blockers BQ123 and BQ788 were applied.

Th e RT-PCR proved basophils to express both, ETAR and ETBR. Th e migratory eff ect of ET-1 [10 -8 M] (p < 0.0001) was signifi cantly inhibited solely by the ETAR inhibitor BQ-123 [10 -6 -10 -12 M]. However, to compare, the histamine release upon ET-1 [10 -8 M] (p < 0.0001) could only be eff ectively blocked by the ETBR inhibitor BQ-788 [10 -8 M] (p < 0.05). Th e fl uorescence microscopy revealed ET-1 to be highly effective in inducing intracellular calcium increase 50 seconds after ET-1 stimulation and lead to a full recovery of ion fl ux 200 seconds later. Th e Western Blot on the downstream enzyme cascade proved ET-1 stimulated basophils to have an activation of p-p38MAPK and p38MAPK compared to untreated basophils, which is known to induce long lasting eff ects by activation of, for example, c-myc, c-fos and c-jun transcription.

Our observations reveal for the fi rst time that ET-1 initiates basophil migration via ETAR and histamine release by ETBR and that these eff ects are mediated by calcium signalling and downstream activation of p38MAPK. Considering the fact that ET-1 and basophils have a crucial role in airway infl ammation, targeting the eff ects of ET-1 by receptor antagonists may be a new option in the treatment of allergic airway disease. A16 ÖGP peutic exercises in patients with chronic obstructive pulmonary disease (COPD).

Aim: To investigate the complex therapeutic infl uence of specialized physical therapy (PT) regarding elderly patients with COPD at different stages of the disease.

Methods: A one year study has been conducted investigating the eff ect of PT applied in hospital and in ambulatory elderly patients in Sofi a. Outcome measures were: spirometry, pulse oximetry, six minutes walking test, Borg scale, Saints' George Respiratory Questionnaire, BODE index, body mass index, pulse and respiratory rate, blood pressure, apnoic tests. 65 patients with COPD divided into 2 groups according to the stage of the disease were studied. First group includes 33 patients (22 women, 11 men, age 68.6 ± 7.3) with an exacerbation of COPD (II-III GOLD), receiving in hospital and ambulatory PT. Second group includes 32 patients (28 women, 4 men, age 71.7 ± 6.9) without an exacerbation of COPD (I -II GOLD), receiving only ambulatory the same PT as the fi rst group. In hospital PT sessions were individually tailored, on 10 daily consecutive days, duration of 20-25 min. Outpatient PT sessions were in groups of 12-20 patients, 30-60 min. Exercise therapy includes breathing techniques and breathing retraining: thoracic and diaphragm breathing; pursed lips breathing; pronouncing various of sounds during prolonged expiration; rhythmic cuing of breathing; controlled walking or slight jogging.

Results: PT improves forced vital capacity, saturation, physical tolerance, apnoic respiratory tests, quality of life and individual prognosis of COPD in patients of fi rst group. Basic dyspnoea and exertional breathlessness decreased. PT improves forced vital capacity, physical tolerance and apnoic respiratory tests in patients of second group.

Conclusions: Our PT program has positive therapeutic eff ect on: bronchopulmonary functional status; breathlessness; physical tolerance; health-related quality of life and prognosis of the disease. Background: Lung transplant recipients (LTRs) are uniquely predisposed in developing severe complications associated with community acquired respiratory viral infections (CARV). We report the outcomes of infl uenza infections in a cohort of 82 screened lung transplant recipients at our center.

Methods: Data were collected from December 2010 to March 2011 on using real-time polymerase chain reaction (PCR) from nasal secretion. During this period 245 patients frequented our out patient department for thoracic surgery. All LTRs (n = 82) with respiratory symptoms were screened. Th ere were 9 (10, 9%) confi rmed cases. H1N1 infection was diagnosed in 5, infl uenza B in 4 lung transplant recipients, median age 36 (26-65) years, with a median of 6 (1, 1-12) years post lung transplantation.

Results: All patients with BOS grade 0 (bronchiolitis obliterans syndrome, n = 5) were treated symptomatically alone, with no further impact on their lung function. Two patients of this group have been vaccinated for seasonal infl uenza. Among the group of patients with pre-existing BOS (n = 4), two lung transplant recipients, one with BOS I, the other with BOS II developed pneumonia and had to be admitted. Th e patient with BOS II died due to acute respiratory distress syndrome (ARDS). Both patients received no vaccination. Th e other two (4.9 ± 2.1 L/min) showing a signifi cant diff erence by paired non-parametric analysis (p < 0.001). COTh ermo was 5.4 ± 1.4 L/min in controls without reaching a signifi cant diff erence to CO Fick in paired non-parametric test. Direct comparison of COTh ermo with CO Fick by agreement analysis revealed a comparable bias between the methods in both groups (0.56 ± 1.10 L/min in patients and 0.65 ± 0.82 L/min in controls) with wider limits of agreement for the patient population (-1.60 to 2.72 L/min versus -0.96 to 2.25 L/min in controls).

Conclusions: Determination of CO by the indirect Fick method can not be used in PAH patients as this method consequently underestimates CO. It can be suggested that the estimated VO 2 parameters are invalid for PAH patients. Background: Emerging evidence indicates that bone-marrow-derived endothelial progenitor cells (EPC) might play a key role in the formation of new vessels. Endothelin-1 (ET-1) modulates diff erent stages of neovascularisation, e.g. proliferation, migration, invasion, protease production and changes in morphogenesis of endothelial cells. We investigated a potential link between the ET system and EPC.

Methods: For all experiments ex vivo generated, characterized and cultivated rat bone marrow-derived EPC were used. Freshly isolated rat pulmonary artery (paEC) and aortic endothelial cells (aEC) served as positive control. Expression of ETA and ETB receptors and detection of prepro-ET and ET converting enzyme (ECE) mRNA were performed by standard RT-PCR.

In calcium (Ca 2+ ) fl ux assays EPC previously loaded with FURA-2 [5 μM] were exposed to ET-1 [10 -6 M and 10 -8 M]. ATP [100 μM] served as positive control. Changes in fl uorescence intensity were measured using a microplate reader. For selective inhibition of receptor subtypes, EPC were pre-incubated with ETRA (BQ123) and ETRB (BQ788) antagonists for 20 min before stimulation with ET-1 [10 -6 M].

Background: Th ere are no large studies about the epidemiology and outcome of patients with COPD treated in intensive care units (ICU). More specifi cally it is unknown, whether the presence of COPD is an independent risk factor for prolonged mechanical ventilation, prolonged weaning and eventually a poor prognosis. Such information is valuable for the planning of resources including respiratory care units and weaning facilities.

Objectives: We speculated that COPD would be an increasing problem in critically ill patients and would be associated with increased morbidity and mortality. Th e objectives of the study were therefore 1. to describe the epidemiology of COPD in patients admitted to the ICU, 2. to determine whether COPD is an independent risk factor for unfavorable outcome.

Methods: We conducted a retrospective study in 87 medical, surgical, and mixed ICUs in Austria, using a prospectively collected database of 194, 453 adults admitted consecutively over a period of eleven years [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] .

Results: COPD was present in 8.6% of all ICU patients. Th e riskadjusted mortality of patients with COPD was higher compared to patients without COPD (observed to expected mortality ratio with 95% confi dence intervals 0.91 [0.90-0.92] vs 1.14 [1.12-1.16], respectively). Th e presence of COPD was an independent risk factor for increased mortality in multivariable regression. Prolonged mechanical ventilation occurred more common in patients with COPD (24%) compared LTRs, one with BOS I the other with BOS II and active vaccination protection were treated with Oseltamivir at the time of the fi rst clinical assessment, without any further respiratory complications. Th erapy with Oseltamivir was only started with clinical assessment within the fi rst 48 hours.

Conclusions: Our review demonstrates a causal link between preexisting BOS, vaccination state and the severeness of respiratory symptoms after infection with community acquired respiratory viruses as well as the clinical eff ectiveness of seasonal infl uenza vaccination especially in BOS patients.

Endobronchial one-way valve implantation in patients with heterogeneous emphysema using interlobar fi ssure analysis-a pilot study Background: Th e aim of the present study was to assess the efficacy of bronchoscopic lung volume reduction (BLVR) using endobronchial one-way valve implantation in patients with emphysema based on a novel radiological treatment algorithm.

Methods: Patients were considered radiologically eligible if at least one of the lungs had a complete oblique fi ssure and a primary target lobe with a destruction score ≥ 55% and a heterogeneity score ≥10%. Patients with a right upper target lobe underwent also right middle lobe treatment in the presence of an incomplete horizontal fi ssure. Primary endpoint was the mean % change in FEV% predicted at 90 days after valve implantation. Secondary endpoints included mean% change in lung volumes and exercise capacity.

Results: A total of 15 patients with severe emphysematous type of COPD (mean FEV1 31%) met clinical and radiological eligibility criteria. BLVR was associated with no signifi cant improvements in primary or secondary endpoints in the overall study population. Five patients (33%) were considered radiological responders with more than 500ml of target lobe volume reduction in HRCT at three months. Th ese patients had a 26% relative increase in FEV1%, 32% increase in maximum workload, and a 24% increase in inspiratory capacity. Th ere was a high rate of serious adverse events including 1 sudden cardiac death within 24 hours and 3 pneumothoraces (20%) during the 3 month period.

Conclusions: BLVR using one-way valve implantation in patients with heterogeneous emphysema and closed interlobar fi ssures may be associated with clinical benefi ts in a small subgroup of patients, at an overall higher risk of serious adverse events P015 Treatment of bronchopleural fi stula using endobronchial one-way valve implantation -a case series Background: Mutations of the Epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) predicts the response to tyrosine kinase inhibitors. Commonly mutations occur more in never smokers, adenocarcinomas, women and East Asians. In the largest European screening trial the frequency of caucasian Spanish patients was 16.6% (1). However, the frequency of EGFR mutations in NSCLC from Austrian patients is unknown.

Objectives to those without (13%), p < 0.0001. Prolonged weaning was also more common in patients with COPD (6%) compared to those without (2%), p < 0.0001. Within all ICU patients with a diagnosis of COPD, 29% had acute respiratory failure as the main cause for ICU admission. During the course of eleven years the incidence of acute respiratory failure due to COPD increased from 1.8% to 3.0% (p < 0.0001) and the use of non-invasive ventilation more than doubled (from 15% to 34%, p < 0.0001). Simultaneously the risk-adjusted mortality of COPD patients decreased.

Conclusions: Acute respiratory failure due to COPD is an increasingly common condition in critically ill patients. Th e presence of COPD is associated with increased mortality and morbidity. Th e improvement of risk-adjusted mortality over time may be attributable to the benefi cial eff ects of non-invasive ventilation.

Lung cancer related and unrelated to smoking is still leading cause of cancer deaths worldwide with an overall survival rate of 15%. Epidermal growth factor receptor (EGFR) kinase mutations occur in over 60% of NSCLC in never-smokers. Most frequent smoking-related mutations impair GTP hydrolysis in Kirsten-Ras (K-Ras), a key oncogene downstream of the EGFR pathway, causing persistent cell growth and proliferation in 20-30% of lung adenocarcinomas.

Although anti-EGFR therapy with erlotinib and geftinib works within 75% of patients with EGFR tyrosine kinase mutated NSCLC, EGFR activity blockers have been reported to be ineff ective against advanced stage K-Ras mutant tumors. In contrast, EGFR amplifi cation is frequently found in NSCLC patients with smoking history, indicating that EGFR plays a role in tumor onset of smoking related adenocarcinomas.

First aim of the project will be to identify the role of EGFR in lung tumors of the K-Ras induced lung cancer mouse model. Th is model allows conditional expression of a constitutive form of K-Ras leading to adenocarcinoma in mice. By crossing conditional EGFR transgenic mice with the K-Ras mutated mice, we will investigate the role of EGFR in onset and progression of lung cancer in more detail.

Another key pathway downstream of EGFR signaling is the signal transducers and activators of transcription (STAT) pathway. STAT-3 regulates important pathways in tumorigenesis, through upregulation of genes encoding apoptosis inhibitors (Bcl-XL, Bcl-2, Mcl-1, survivin). In patient samples and NSCLC cell lines nuclear pSTAT3 is upregulated and correlates with subsequent suppression of apoptosis of NSCLC tumors. In order to investigate the role of STAT3 in lung tumors, we will cross conditional STAT3 transgenic mice with the K-Ras lung cancer mouse model. Within the second approach the molecular mechanisms linking STAT3 and lung cancer will be addressed in more detail.

In a retrospective study we analysed all PCR-proven H1N1 cases from the infl uenza season 2009/2010 treated within the styrian "LKH hospital network". For this purpose all PCR-postive case fi les were reviewed and data regarding clinical presentation, laboratory and radiological fi ndings, treatment, outcome and preexisting underlying chronic illnesses were systematically collected. In a second step the same data collection was performed in a group of PCR-negative patients, which were tested during the infl uenza season 2009/2010 for infl uenza-like illness. Th e data from the PCR-positive group were compared to the data from the PCR-negative group.

Necrotizing arthritis of right talo-navicular joints -when arthrodesis fails, it's TB Background: TB can occur in any tissue including bones and joints involving most often the spine and monoarticular weight bearing joints. With trauma, surgery or implantation of endoprosthesis TB may arise insidiously.

Case Reports: Two case reports of necrotizing tuberculous arthritis/synovitis of the right talo-navicular joint 63-64 years after primary TB are reported -in a male (FEF68m) and female patient (SCr69f ). It was mistaken for noninfectious necrotizing arthritis. Arthrodesis of the talo-navicular joint was performed 20 and 7 months after onset of symptoms when antiinfl ammatory measures failed. But healing did not occur.

In FEF68 m the histology revealed granulation tissue with granulomas like a foreign body reaction, but no material for microbiology was sent. In SCr69f neither histology nor microbiology were done.

In FEF68 m IGRA was negative but TST positive twice. In him the histology of non-caseating epitheloid granulomas in a lichenoid lesion of the right cheek pointed towards sarcoidosis. Prednisone cleared the facial lesion but did not change the hypermetabolic activity on PET-CT in the right middle foot.

In SCr69f all immunological TB-tests were positive, but a needle biopsy of the necrotized talus and os cuneiforme inconclusive. Delay of 39 and 24 months without combined anti-TB treatment allowed progressive destruction of joints.

Conclusions: Paucibacillary tuberculous necrotizing synovio-arthritis of talo-navicular joints can be mistaken to be degenerative. TB at/after arthrodesis could be successfully managed if diagnosed early and treated properly. Decreased morbidity would have resulted, but indicators of TB (history, positive TST) were not appreciated, and biopsies at surgery not worked up with ZN-stain, PCR and TB-culture. Histology might be misleading or misread. MR details the morphology while 18-FDG-PET-CT reveals ongoing metabolic hyperactivity.

Out of 98 patients (mean age: 63 ± 9 years, 20 female, 78 male), 65 underwent curative surgery including either resection alone (n = 21) or surgery within multimodality treatment (n = 44). In 33 patients, chemo-and/or radiotherapy without curative resection was performed. Mean overall survival (OS) of all patients was 541 days (95% confi dence interval [CI]: 442-640 days). Patients undergoing multimodal therapy had the signifi cant longer survival (OS: 742 days, CI: 566-919 days) than patients treated with chemo-and/or radiotherapy alone (OS: 472 days, CI: 359-585 days; log rank: p = 0.018) or patients undergoing surgery alone (OS: 231 days, CI: 114-349 days; log rank: p = 0.006). Th e most frequent histological subtype was the epitheloid (n = 64), followed by the biphasic (n = 21) and the sarcomatoid (n = 4; missing: n = 9). Patients with non-epitheloid histology had the signifi cant worse outcome (non-epitheloid: OS: 358 days, CI: 208-508 days vs. epitheloid: OS: 632 days; CI: 495-770 days; log rank: p = 0.016). Furthermore, postoperative ICU stay had a signifi cant impact on OS (Cox regression: p = 0.003).

Conclusions: Treatment modality and histology had a signifi cant impact on MPM outcome. Postoperative ICU stay was found to be prognostic within the surgical treated subgroup. Background: Pancoast tumors are a rare disease entity associated with poor prognosis. Induction chemoradio-therapy before surgical resection is the standard treatment nowadays. However, there is little knowledge regarding the impact of advanced N stages on multimodal treatment protocols.

Methods and results: We retrospectively evaluated patients presenting with a pulmonary sulcus tumor at our department from 1998 -2011. A total of 47 patients were included in the analysis. At the time of diagnosis 39% of patients had a positive N staging (7% N1, 23% N2, 9% N3). 88% of patients received an induction chemotherapy or a combined radio-chemotherapy. After induction therapy curative resections were performed. Pathological evaluation revealed that in 47% of patients with initially positive lymph nodes there was still evidence of a microscopic disease. Th is subtype of patients had an unfavourable prognosis when compared to N stage responders or patients without lymph node involvement at time of diagnosis (median survival: 24 months, 41 months, 145 months, respectively). Interestingly, prognosis was independent from the extent of resection (laminectomy, vascular replacements, resections of the brachial plexus or the clavicula).

Conclusions: Patients with advanced N staging should not be excluded from a multimodal treatment protocol with curative intent. N downstaging to pN0 after induction therapy increases median survival by 17 months, however, patients with initially cN0 disease have by far the best outcome. . Th e highest percentage of discordance was depicted in chronic obstructive lung diseases (12 of 344), with the fi nal diagnosis of UIP (n = 4), chronic interstitial fi brosis (n = 4), silicosis (n = 2), LAM (n = 1) and sarcoidosis (n = 1). 16 patients who were referred with the diagnosis of an interstitial lung disease had predominantly emphysema (n = 12), bronchiectasis (n = 2) and histiocytosis X (n = 2). Expanded results included Aspergillus (n = 11) and mycobacterial (n = 16) infections, carcinomas (n = 10), cystic adenomatoid dysplasia (n = 1) and carcinoid (n = 1).

However, short-and long-term survival was not diff erent in patients with diff erent diagnoses, malignancies or implanted infections. Interestingly all mycobacterial infections and all malignancies occurred in patients with COPD.

Conclusions: On account of this high rate of discrepancies and its possible infl uence on survival , frequently repeated clinicopathologic investigations should be performed during the waiting list period. Alpha-1 Antitrypsin Defi ciency (AATD) is a genetic disorder with decreased levels of AAT protein causing lung disease among adults. Th e most common lung disease of AATD-patients is COPD, which occurs with a prevalence of 1,220.000 in Austria, while AATD is thought to be diagnosed in ~5% of patients with AAT defi ciency. Th us, patients with the disease are unaware and do not receive the necessary and lung tissue saving augmentation therapy using human alpha-1 antitrypsin. An early diagnosis and initiation of the therapy are crucial factors for the later course of disease.

Since 2001, Austria is a member of the Alpha One International Registry (AIR). In order to simplify administration and to prevent data loss the Austrian Alpha-1 Lung Registry, a new web-based national registry, was introduced. Within Austria, seven centres of excellence have been established with a direct access to the registry.

Until today, the Austrian Alpha-1 Lung Registry includes data of 178 patients, of whom 40.4% are female. Th e average age of the patients is 49.8 years, and the average age of patients at the time of diagnosis is 45 years. 70.8% of the AATD-patients are or were smokers. Th e detected comorbidities (hypertension is most common, 11,8%) do not show any relationship with the underlying disease. 42% of registered patients receive augmentation therapy with Prolastin ® . After initiation of treatment median FEV1 did not change signifi cantly before and after broncholysis. Further follow-up studies in order to analyse the progression of FEV1 are planned and will be carried out as soon as suffi cient data from the registry is available.

Summarizing these data, it can be concluded that Austria has to enhance its eff orts in order to increase the number of diagnosed cases and to provide the appropriate therapy to all AATD-patients. Augmentation therapy with alpha-1 antitrypsin maintains lung function in AATD-patients.

Comparison between referral and explant diagnoses in lung transplant recipients: Discrepancies and additional fi ndings Background: We report the fi ndings on 15 Patients which underwent tumor resection in the lung using SHFJV. SHFJV is defi ned as weight based ventilation combined with superposition of two jetstreams. Th e high frequency jet-stream is responsible for the oxygenation and the normofrequency jet eliminates the CO 2 . In all patients preoperatively lung function was severely restricted.

Methods: Basic Patient characteristics (mean/SD): FEV1 below 2.1 ± 1 litre O 2 saturation below 92% at room air conditions PaO 2 71 mmHg ± 5 mmHg PaCO 2 41 mmHg ± mmHg Based upon these facts conventional single lung ventilation during surgery was considered to be most likely insuffi cient and therefore ventilation with SHFJV was prepared for standby. Th e trachea was intubated with a double lung tube. After one unsuccessful trial of conventional single lung ventilation using 100% oxygen we switched to SHFJV before any signs of hypoxic pulmonary vasoconstriction and desaturation occurred. Oxygenation goals were a PaO 2 between 80 mmHg and 100 mmHg and a PaCO 2 level between 35 mmHg and 45 mmHg. We ventilated the dependent lung by conventional ventilation (IPPV) and the non-dependent lung by jet-ventilation. Th e aim of this study was to retrospectively assess the clinical outcome of patients undergoing a trimodality therapy regime (induction chemoradiotherapy and curative resection) for advanced stage NSCLC.

Methods: A retrospective review of all consecutive patients undergoing induction chemoradiotherapy followed by curative resection between 1998 and 2010 at our institution was conducted.

Results: A total of 49 patients received induction chemo-and radiotherapy followed by radical surgery, including 11 patients (22.4%) with pancoast tumors. Th e patients comprised 34 (69.4%) men and 15 (30.6 %) women with a mean age of 54.5 years at the time of resection. Surgical procedures consisted of 3 segmental resections, 24 lobectomies, 3 bilobectomies, and 20 pneumonectomies (11 extra-and 9 intrapericardial). In 48 patients a complete resection (R0) was achieved. 21 (42.9%) patients had a postoperative complication, ranging from 29.2% after lobectomy to 63% after pneumonectomy (p = 0.23). No deaths occurred within 30 days. Overall 3-year survival rate was 45%. Overall disease free survival (DFS) will be presented at the conference. In patients with pneumonectomy 3-year survival was significantly better than in patients with lobectomy (55% vs. 32%, p = 0.039; HR 0.386; 95% CI 0.153 -0.976).

Conclusions: Within a multimodal therapy strategy favorable results for patients in advanced stage non-small cell lung cancer can be achieved. In this series survival in patients undergoing pneumonectomy tended to be superior to patients with lobectomy.

Th e physiological range of pulmonary vascular resistance (PVR) and total pulmonary resistance (TPR) and the infl uence of exercise, age, and posture have been a matter of debate for many years.

We performed a systematic literature review including all right heart catheterisation data where individual PVR and TPR of healthy subjects both at rest and exercise were available. Data were stratifi ed according to age, exercise level and posture.

According to the selection criteria, n = 222 subjects from 24 diff erent studies were included into this analysis. Supine resting PVR in subjects < 24 yr, 24-50 yr, 51-69 yr, and ≥70 yr was 61 ± 23, 69 ± 28, 86 ± 15, and 90 ± 39 dyn*s*cm -5 . Corresponding TPR was 165 ± 50, 164 ± 46, 226 ± 64, and 223 ± 45 dyn*s*cm -5 . During moderate exercise, in subjects ≤50 yr, 85% increase in cardiac output (CO) was associated with 25% decrease in TPR (p < 0.0001) and 12% decrease in PVR (p < 0.01). Between 51-69 yr there was no signifi cant TPR and PVR decrease. In individuals ≥ 70 yr TPR even increased by 17% (p = 0.01), while PVR did not change signifi cantly. At higher exercise levels, TPR decreased in all age groups. In the upright position, based on a limited number of data, resting TPR and PVR were higher than supine and decreased more prominently during exercise, suggesting the release of resting pulmonary vasoconstriction.

Th ese data may form a basis to defi ne normal pulmonary vascular resistances at rest and exercise. Background: Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders that are characterized by ineff ective hematopoiesis, morphological dysplasia, peripheral blood cytopenias and progressive bone marrow failure. Myeloproliferative disorders, thrombocytosis and thrombocytopenia have been identifi ed as risk factors for pulmonary hypertension (PH) but it is unknown if MDS bears an increased risk for PH. Th e aim of this study was to investigate the prevalence of PH in patients with MDS.

Methods: Consecutive MDS patients of the hematology Outpatient Clinic of the Medical University of Graz were enrolled in a PH screening program and underwent echocardiography. PH was suspected if resting systolic pulmonary arterial pressure (SPAP) exceeded 40 mmHg.

Six minute walk distance (6MWD), pulmonary function test (PFT), laboratory tests including N-terminal pro brain natriuretic peptide (NT-proBNP) and WHO functional class were determined in each patient.

Basic patient characteristics (mean ± SD): Age 59.7 ± 13.8 FEV1 (liter) 2.79 ± 0.58 PaCO 2 (mmHg) 35.52 ± 6 Findings after 10 minutes SHFJV: PaCO 2 (mmHg) 35.13 ± 11.78* ETCO 2 (mmHg) 27.48 ± 4.81 

The presence of right axis deviation indicates pulmonary hypertension in a risk population G. Kovacs 1,2 , X. Kqiku 2 , V. Foris 1 , M. Tscherner 1,2 , N. Troester 2 , S. Scheidl 2 , C. Hesse 2 , H. Olschewski 1, 2 Background: Pulmonary hypertension (PH) is diagnosed by right heart catheterization, but non-invasive methods play an important role in the screening and the follow-up of the disease. ECG is routinely performed in the clinical work-up of patients but its clinical value has not been defi ned. We hypothesized that a simple parameter, such as the presence of right axis deviation (RAD) in the standard ECG might be a useful tool in the diagnosis and follow up of patients with PH.

Methods: We retrospectively analysed all patients who received at least one right heart catheterization and a routine ECG in our department of pulmonology between 2005 and 2010. Th e indication for invasive hemodynamic assessment was heterogeneous, the pretest probability of PH was about 50%. We determined the ratio of the S and R waves in lead I in each patient, a value ≥1 (≥90°) was considered as RAD. Th e investigator was blinded to the right heart catheterization results. Th e sensitivity and specifi city of RAD to predict PH (mean PAP ≥ 25 mmHg) was determined.

Results: We included n = 317 patients in this study. RAD was present in n = 71 of these patients. Within these, PH was detected in n = 65 patients, and was missing in n = 6 subjects. In n = 246 patients without RAD, PH was present in n = 87 patients. Th e specifi city of RAD for PH was 96%, whereas the sensitivity was merely 43%. Accordingly, the positive predictive value of RAD to predict PH was 92%, while its negative predictive value to rule out PH was just 35%. In patients with RAD the likelihood of PH was signifi cantly higher (p < 0,001).

Conclusions: Our retrospective analysis on a relatively large, heterogenous cohort of subjects including patients with and without PH suggests that the presence of RAD in the ECG has a high specifi city but a low sensitivity for PH. Th is simple method may help to recognize PH patients within a population at risk for PH. In order to determine its appropriate role in a diagnostic algorithm, prospective, population based studies are needed. abstracts ÖGP Jahrestagung 2011 wkw 17-18/2011 © Springer-Verlag A23 ÖGP cating that endogenously-driven cAMP synthesis enables the PDE4 inhibitor to act.

Conclusions: Rofl umilast N-oxide diminished TGFß1-induced proliferation of human lung fi broblasts. In parallel, rofl umilast N-oxide reversed the TGFß1-induced loss in p27(kip1) protein perhaps emanating from an observed reduction of Skp2 up-regulated by TGFß1. Future studies shall decipher whether the eff ects on Skp2 and p27(kip1) account for the inhibition of HLF proliferation by rofl umilast N-oxide.

Work-up of solitary pulmonary nodules: Diagnostic yield of electromagnetic navigation bronchoscopy (ENB) in combination with PET-CT and rapid-on-site cytopathologic evaluation (ROSE) Results: Fourty two MDS patients (female n = 17; male n = 25, age 70 ± 12 years, disease onset 4 ± 7 years, NYHA functional class I:II:III:IV = 20 : 16 : 6 : 0) underwent echocardiography. SPAP > 40 mmHg was found in 6/42 patients (SPAP: 56 ± 9 mmHg), 36/42 patients had SPAP ≤ 40 mmHg (29 ± 5 mmHg). Compared to patients with normal SPAP, patients with increased SPAP were older (79 ± 9 vs. 69 ± 12 years), had a decreased right ventricular function (TAPSE: 14 ± 2 vs. 16 ± 3), a larger left atrium (46 ± 5 mm vs. 36 ± 9 mm measured in the parasternal long axis), a lower left ventricular systolic function (fractional shortening: 30 ± 11 vs. 39 ± 8%) a lower 6MWD (275 ± 117 vs. 444 ± 100 m) and higher NT proBNP (2708 ± 2845 vs. 313 ± 252 pg/ml). In 4/6 patients with SPAP > 40 mmHg a relevant diastolic dysfunction of the left ventricle was present.

Conclusions: According to our data, increased SPAP values may be present in about 15% of MDS patients. Th e reason of PAP increase may be multifactoral, postcapillary factors probably playing a relevant role.

Rofl umilast-N-Oxide, a PDE4 inhibitor, partially reversed an increase in Skp2, a loss in p27(kip1) and inhibits proliferation in human lung fi broblasts secondary to TGFβ1 Background: Proliferation of human lung fi broblasts (HLF) may foster pulmonary remodelling as seen in COPD. Th e cell cycle is tightly controlled by a network of cyclins, cyclin-dependent kinases and their inhibitors (CDKI) such as p27(kip1). In late G1, p27(kip1) recruits to S-phase kinase-associated protein-2 (Skp2) resulting in p27(kip1) proteasomal degradation facilitating S-phase entry. In smooth muscle cells, cAMP suppresses Skp2, enhances p27(kip1), thus preventing proliferation. Th is study explores whether the phosphodiesterase-4 (PDE4) inhibitor rofl umilast N-oxide, the active metabolite of rofl umilast approved for severe COPD in EU and under review by the US FDA, modifi es TGFß1-induced proliferation of HLF and the expression of the CDKI p27(kip1) and Skp2.

Methods: Normal HLF cultured in 0.5% FCS were incubated without (control) or with TGFß1 (1 ng ml -1 ) following preincubation (30 min) with rofl umilast-N-oxide (2 nM or 1 μM), forskolin (10 μM) or dideoxyadenosine (DDA, 100 μM) or vehicle (DMSO). Rofl umilast Noxide at 1 μM completely and selectively blocks PDE4, and 2nM is close to mean steady state plasma levels in clinical trials. Cell proliferation was determined after 72h by cell counting. To assess eff ects on p27(kip1) and Skp2 protein levels, incubations were terminated at 3h after TGFß1 and cellular proteins were extracted. p27(kip1) and Skp2 were detected by immunoblotting with ß-actin as loading control. Blots were analysed by densitometry and related to the loading control. Results were given as the means ± SD from 3 experiments.

Results: Incubation of HLF with TGFß1 (1 ng ml -1 ) enhanced their proliferation by 1.6 ± 0.1 fold of control (p < 0.05). Rofl umilast N-oxide at 2 nM and 1 μM curbed the TGFß1-induced increment by 50% and 58% to 1.3 ± 0.06 fold (p < 0.05) and 1.25 ± 0.05 fold of control (p < 0.05). Forskolin abolished the TGFß1-induced proliferation.

Exposing HLF over 3h to TGFß1 (1 ng ml -1 ) reduced p27(kip1) to 69 ± 20% (p < 0.05) but enhanced SKP2 protein to 149 ± 10% (p < 0.05) of control. Rofl umilast N-oxide almost fully rescued the TGFß1-induced loss in p27(kip1) to 92 ± 9% of control at 2 nM and 96 ± 4% at 1 μM (p < 0.05) while it attenuated the increment in Skp2 by 78% (2 nM) and 87% (1 μM) (p < 0.05). Th is eff ect was abolished by DDA indi-abstracts ÖGP Jahrestagung 2011 © Springer-Verlag 17-18/2011 wkw A24 ÖGP Weyer. Th e active program consisted of endurance and strength training each of them three times a week for half an hour and an inspiratory muscle training for patients with a PI max below 7 kPsa and, furthermore, a Patient education including 4 lessons. Methods: From 2009 to 2010 data of all 533 COPD patients participating the inpatient rehabilitation in Weyer for 3-4 weeks were collected, especially the CRQ (chronic respiratory questionnaire) and the 6MWT (6-minute walking test) at the beginning and the end of the program.

Results: Mean age 62. 7 (40 to 89) years, 64.35% men and 35.65% women. Mean FEV1 was 1.35 or 44.76%. GOLD-stage 0 = 1.5%, stage 1 = 10.13%, stage 2 = 23.08%, stage 3 = 25.33%, stage 4 = 39.96%.

Th e distribution of the BODE-score showed 36.72% of the patients to be in the 1st Quartile, 28.06% in the 2nd Quartile, 19.59% in the 3rd Quartile and 15.63% in the 4th Quartile.

34.52% of the patients were treated with long time oxygen supplementation and 13.51% had a global insuffi ciency.

19.50% were smokers, 72.33% ex-smokers and 8.18% never have smoked.

Th e mean of the 6MWT at the beginning resulted in 369.11 m, and increased to 413.92 m at the end. Th e improvement of 44.81 m exceeded the minimal important clinical diff erence of 28 meter (Puhan 2011).

Th e CRQ domains were as follows: Dyspnoe at baseline 3.44 and discharge 3.68 (diff erence 0.24 = clinically not relevant).

Fatigue at baseline 4.23 and at discharge 4.91 (diff erence 0.68 = clinically relevant).

Emotional function at baseline 4.38 and at discharge 5.23 (diff erence 0.85 = clinically relevant).

Mastery at baseline 4.56 and at discharge 5.22 (diff erence 0.66 = clinically relevant).

Conclusions: For three to four-week inpatient rehabilitation clinically relevant benefi ts were found in the CRQ domains fatigue, emotional function, and mastery, as well as in the 6MWT. Th e distribution of the BODE-score showed / resulted in 36.72% in the 1st Quartile, 28.06% in the 2nd Quartile, 19.59% in the 3rd Quartile and 15.63% in the 4th Quartile.

34.52% of the patients were treated with long time oxygen supplementation and 13.51% had a global insuffi ciency.

20% were smokers, 72% ex-smokers and the rest never have smoked.

Th e following comorbidities were found: Hypertension = 53.38%, Coronary heart disease = 14.29%, Chronic heart disease = 11.84%, Insulin Dependent Diabetes = 3.01%, Non In- Background: Hypoxia leads to aggressive cancer growth. To identify cancer specifi c, hypoxia induced pathways is a major aim. Hypoxia not only aff ects neoplastic tumor cells, but also the supporting stroma. We thus established a novel ex vivo lung cancer model for hypoxic adaptation with preserved tumor stroma and 3D-structure.

Experimental design: Non-small cell lung cancer (NSCLC) fragments were cultured ex vivo under hypoxia or normoxia for three days. cDNA microarray analysis was performed in hypoxic and normoxic lung cancer fragments from ten patients. Association of hypoxia regulated genes and survival was assessed in four publically available microarray series including 342 NSCLC patients.

Results: Ex vivo cultured lung cancer fragments were viable, apoptosis rates were not increased by hypoxic treatment. Hypoxiainducible factor 1α was stabilized and signifi cant upregulation of the hypoxia marker carbonic anhydrase IX was observed under hypoxia. Microarray analysis identifi ed 107 signifi cantly regulated genes with at least two-fold expression change in hypoxic compared to normoxic fragments. However, only four genes were signifi cantly regulated in both subtypes, adenocarcinoma and squamous cell carcinoma. We found an unexpected induction of neprilysin (membrane metalloendopeptidase, neutral endopeptidase, NEP, CD10) under hypoxia, which was confi rmed using quantitative PCR. Neprilysin expression was signifi cantly associated with poor overall survival in NSCLC patients treated with surgery (P = 0.002).

Conclusions: Our study demonstrates for the fi rst time that the membrane bound metallopeptidase neprilysin is upregulated by hypoxia and that it is an adverse prognostic factor in lung cancer. Neprilysin might thus serve as a hypoxia related target for anti-cancer therapy.

Which benefi ts can COPD patients derive from inpatient rehabilitation? Background: Nearly all studies concerning rehabilitation are performed with selected patients. In order to investigate the benefi ts for unselected COPD patients we performed a study with all COPD patients who attended an 3 to 4 weeks inpatient rehabilitation stay in abstracts ÖGP Jahrestagung 2011 wkw 17-18/2011 © Springer-Verlag A25 ÖGP Methods: We studied 63 patients (mean Age 55 ± 11 yrs, mean BMI 36 ± 7 kg/sqm, mean AHI 48 ± 30/hr, ESS 11 ± 5) who received fi xed or auto-adjusted CPAP treatment for OSAS at our institution. All patients underwent a standardized educational session and mask fi tting by experienced staff . Data on treatment adherence and mask leakage was collected for approximately 6 months after initiation of CPAP.

Results: Mean ± standard deviation days of CPAP use was 176 ± 82 days, percentage of days with CPAP usage 84 ± 18%, and percentage of days with at least 4 hours CPAP use/night 71 ± 24%. Th ere was a signifi cant inverse relationship between CPAP adherence using Kribbs criteria and average time spent with mask leak per night (r = -0.362, p < 0.01). Patients with good adherence (n = 42), defi ned as CPAP use > 4 hours per night on at least 5 days per week, were compared with those who used their device less frequently (n = 21). Th ere were no signifi cant diff erences between baseline characteristics, residual AHI or therapeutic CPAP pressure between groups. Patients with poor CPAP adherence, however, had signifi cantly higher average mask leakage fl ow (39 ± 8 litres/min vs. 34 ± 6 litres/min, p < 0.01) and higher time spent with mask leakage per night (3.7 ± 6 min/night vs. 7.7 ± 10 min/night, p < 0.05) than those with good adherence.

Conclusions: Mask leakage may infl uence treatment adherence with CPAP for OSAS. Th ymomas are rare malign tumors of the mediastinum. We want to report our experience with the resection of thymomas at our institution in the years 2001 to 2010. In the indicated time period a total of 84 resections were performed. 72 patients who underwent surgery for thymoma were analyzed for survival (overall, recurrence free), modifi ed Masaoka stage, WHO type, type and completeness of resection, recurrences, the occurrence of myasthenia gravis, neoadjuvant and adjuvant therapy. 9.7% of cases showed tumor recurrence, 6.9% tumor progression. Patients admitted present with Masaoka stage I (29.2%), stage II (43.1%), stage III (13.9%) and stage IV (13.9%). Th e following WHO types were found: type A (19.4%), type AB (5.6%), type B1 (6.9%), type B2 (22.2%), type B3 (12.5%), thymic carcinoma (19.4%), combined thymomas (12.5%, most frequently B2/B3) and micronodular thymoma (1.4%). Myasthenia Gravis was present in 26.4% of cases. In about 88.9% of cases a complete resection could be reached. Using Overall Survival as outcome measure, the 1 year survival rate was 97%, the 5 year survival rate was 87%. After 1 year 95% of patients were free from recurrence, after 4 years 89% of patients. Progression occurs in 50% of patients one year after incomplete resection. We will discuss the current surgical treatment strategy of thymomas and multimodal approaches for advanced thymomas. 17.30% had 1 comorbidity, 23.50% two, 12.78% three comorbidities, 8.65% four and 6.57% fi ve or more than fi ve.

Conclusions: Th e inpatient rehabilitation of COPD patients revealed numerous comorbid conditions that require extended therapy and training.

Bactericidal activity of N-chlorotaurine against Chlamydia pneumoniae and Chlamydia trachomatis Chlamydia pneumoniae causes infections of both the lower and upper respiratory tract, such as pneumonia, bronchitis, pharyngitis and sinusitis. In the last few years, it has also been implicated as an infectious trigger for acute exacerbations of asthma and COPD.

N-chlorotaurine, the N-chloro derivative of the amino acid taurine, is a mild endogenous long-lived oxidant, which is thought to exert immune-regulatory and antimicrobial properties during infl ammation. Th e sodium salt of N-chlorotaurine (Cl-HN-CH 2 -CH 2 -SO 3 -Na, NCT) can be synthesized chemically and is very well soluble in water. Th e 1% aqueous solution of NCT has broad-spectrum bactericidal, fungicidal, virucidal, and protozoocidal activity. NCT proved to be very well tolerated by human tissue and can be used topically at diff erent body sites to treat infections, e.g. in the human eye, on the skin, in the ear and paranasal sinuses, in the oral cavity, and in the urinary tract.

NCT at concentrations of 0.1% and 1% completely inactivated C. pneumoniae and C. trachomatis serovars A and D after a minimal incubation time of 1 min thus preventing any further chlamydial growth in culture after exposure to the compound. Th ese concentrations can therefore be considered chlamydiacidal. Exposure to 0.01% (550 μM) NCT for up to 30 min did not interfere with the formation of inclusion bodies. Th ese results were identical for chlamydial inocula of either 10 3 IFU or 10 4 IFU.

As a conclusion, NCT at concentrations of 0.1 and 1% (5.5. and 55 mM, respectively) leads to inactivation of the obligate intracellular chlamydiae and may be considered for topical treatment of infections caused by these pathogens, too.

Background: Dynamic hyperinfl ation is associated with exercise limitation in patients with chronic obstructive pulmonary disease (COPD). Inspiratory muscle training (IMT) has been shown to positively infl uence exercice capacity in COPD. Th e aim of the study was to analyze the eff ects of IMT on exercise capacity, dyspnea and inspiratory fraction (IF) during exercise in patients with COPD.

Methods: Daily inspiratory muscle strength and endurance training (training device: Respifi t S TM ) was performed for 8 weeks in 10 patients with COPD GOLD II and III. 10 patients with COPD II and III served as a control group.

Maximal inspiratory pressure (Pi max) and endurance time during resistive breathing manouvers (tlim) served as parameter for inspiratory muscle capacity.

Before and after training the patients performed an incremental symptom limited excercise test to maximum and a constant load test on a cycle ergometer at 75% of the peak work rate obtained in the pretraining incremental test. Endurance time (ET) was defi ned as the duration of loaded pedalling.

Inspiratory capacity (IC) and therefore inspiratory fraction (IF = IC/TLC) served as parameter for dynamic hyperinfl ation. BORG Scale was used for dyspnea evaluation.

Results: Following 8 weeks of IMT there was a statistically significant improvement of Pi max from 7.75 ± 0.47 to 9.15 ± 0.73 kPa (p < 0.01) and of tlim from 348 ± 54 to 467 ± 58 s (p < 0.01) in the training group but not in the control group.

Concerning incremental exercise test we could observe following results: there was a signifi cant increase of IF (from 0.41 ± 0.05 to 0.45 ± 0.05, p < 0.01) indicating decreased dynamic hyperinfl ation. Further on the ratio of bf/VE decreased signifi cantly (from 0.48 ± 0.11 to 0.46 ± 0.13) indicating improved breathing pattern.

A signifi cant decrease in perception of dyspnoea (BORG Scale) was also measured.

Peak work rate (Watt max) remained constant. Concerning constant load cycle ergometer test we could also observe an signifi cant improvement of IC and therefore of IF, improvement of breathing pattern and reduction of dyspnoea sensation.

In addition Endurance time (ET in seconds) was signifi cantly greater (734 ± 74 sec) than before IMT (597 ± 80.8 sec, p < 0.01) Background: Malignant pleural mesothelioma (MPM) is a highly aggressive and therapy-resistant tumor with rising incidence related to asbestos exposure during the 2nd half of the 20th century. Growth factors of the activin family are deregulated in a number of diff erent malignancies including hepatocellular carcinoma, NSCLC and esophageal cancer. Here we present evidence that activin signals may contribute to aggressiveness of MPM cells.

Methods: Expression of activin subunits and activin receptors was determined in a panel of 10 MPM cell lines by conventional and real-time PCR. Moreover, activin βA (INHBA) expression was analyzed by immunohistochemistry in MPM tissue samples. To analyze functional implications of activin signals, MPM cell models were exposed to exogenous activin A, siRNA-mediated INHBA silencing or activin receptor inhibitors. MTT and clonogenic growth assays were used to assess cell proliferation and survival. Cell migration was analyzed by scratch and transwell assays, and Smad2 phosphorylation by Western blot as readout for activation of the activin/TGFbeta signaling pathway.

Results: Expression analysis revealed high expression of activin βA and activin receptors in most MPM cell lines compared to nonmalignant mesothelial cells. Immunohistochemistry in tissue sections of MPM patients showed intense cytoplasmic staining for activin A in the tumor cells of a subset of the cases analyzed. Treatment with activin A lead to a strong induction of Smad2 phosphorylation in MPM cell models and stimulated growth and clonogenicity in a subset of cell lines. Silencing of INHBA in contrast lead to reduced growth, clonogenic survival and migration of MPM cell models, demonstrating the important role of INHBA expression for MPM cells. Targeting activin receptors with two diff erent kinase inhibitors (SB431542, A8301) confi rmed these results.

Conclusions: Th ese data suggest that deregulated INHBA expression contributes to the malignant phenotype of MPM cells and that activin signals should be further evaluated as therapeutic targets.

Correlation between blood lactate concentration and base excess during exercise Background: Th e change of blood lactate concentration during exercise is an important parameter describing metabolic changes of the circulation and the state of metabolic reserves. Th e goal of this study was to examine if the change of base excess allows the estimation of the changes in lactate concentration during cardiopulmonary exercise testing (CPET).

Patients and methods: All CPET examinations in the Pulmonology Outpatienz Clinic of the Medical University of Graz between 2007 and 2010 were included in this retrospective analysis where both blood lactate and base excess values were available. Blood lactate and base excess were determined at rest, at maximal exercise, at three and at eight minutes after exercise by using an ABL 800 Flex (Radiometer, Copenhagen) blood gas analyser. Th e correlation between blood lactate and base excess was examined at each time point in all of the patients and in subgroups based on the underlying disease, sex, age, lung function, exercise capacity.

Background: COPD exacerbations are associated with a substantial patient and healthcare burden, which is greater for frequent exacerbations. Th is analysis studied the eff ect of rofl umilast on moderate or severe exacerbations by exacerbation history using pooled data from two 12-month studies.

Methods: M2-124 and M2-125 were replicate, randomised, placebo-controlled, double-blind, multicentre trials in COPD patients with severe-to-very severe airfl ow obstruction, a history of exacerbations and chronic bronchitis. Patients were randomised to rofl umilast 500 μg (n = 1537) or placebo once daily (n = 1554) for 12 months.

Results: Th e rate of frequent exacerbations was lower with rofl umilast than placebo: patients with 2 exacerbations: 11.5% with rofl umilast vs 13.6% with placebo; with 3: 5.9% vs 6.8%; with 4: 2.4% vs 3.5%; with 5: 1.0% vs 2.1%, and with ≥6: 0.6% vs 1.5%. Th e mean exacerbation rate per patient per year was signifi cantly lower with rofl umilast than placebo in patients with <2 exacerbations in the previous year (0.96 vs 1.15, -16.5%; p = 0.006). Th e diff erence between rofl umilast and placebo was greater in patients with ≥2 exacerbations in the previous year (1.51 vs 1.95, -22.3%; p = 0.002). A benefi t was also seen with rofl umilast vs placebo for time to fi rst (hazard ratio [HR] 0.89, p = 0.019), second (HR 0.79, p = 0.001) and third exacerbation (HR 0.73, p = 0.003).

Conclusions: Frequency of exacerbations was lower and time to exacerbation was longer with rofl umilast than placebo. Th e greatest benefi t from rofl umilast was seen in patients with a history of frequent exacerbations (≥2/year). Fig. 1. (Abstract P046) . Reinfusion of autologous splenic B-lymphocytes in previously splenectomized mice normalized thrombus resolution Background: Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterized by frequent resistance to chemoand radiotherapy. Fibroblast growth factors (FGF) and their receptors (FGFR) contribute to malignant growth in several tumor types but in case of MPM their role is poorly understood so far. Aim of the present study was to investigate the expression and impact of FGFs and FG-FRs in MPM and to evaluate their potential as therapeutic targets.

Methods: Expression of all known FGF and FGFR genes was assessed by qRT PCR in MPM cell lines (n = 10) and normal mesothelial cells. FGFR-specifi c tyrosine kinase inhibitors and an adenovirus expressing dominant-negative FGFR were used to block FGF signal transduction in these cell models. MTT and clonogenic assays as well due to suspicion of pulmonary tuberculosis with a cavitating lesion in the right upper lobe. A diagnostic bronchoscopy was performed, with the result of a purulent infl ammation, without evidence of malignancy or tuberculosis. Th ese fi ndings were further corroborated when tb culture results showed no growth of mycobacteria. Following bronchoscopy, the patient admitted to sniffi ng (or "snorting") prescribed benzodiazepines repeatedly.

Discussion: Amongst patients with multiple drug use, alternate routes of administration of prescribed drugs have been observed. While i.v. administration of heroin substitutes such as methadone is a fairly well-known phenomenon in Austria, sniffi ng or snorting of tablets as described in the present case report seems to be a less common practice.

Medical literature only provides individual case reports on the above practice. One Australian investigation of heroin abuse reports that, of 10 heroin related deaths investigated, four occurred after nasal application. A history of polytoxicomania should therefore prompt discussion of drug habits in patients with atypical infections possibly resulting from alternate administration routes of prescribed and of illegal drugs.

A multidisciplinary weaning and extubation regime leads to relevant reduction of weaning and ventilation time P. Schandl, S. Heil, B. Gustorff Department of Anaesthesiology and Intensive Care, Wilhelminenspital, Vienna, Austria Background: Th e use of a multidisciplinary weaning protocol and the ensuing assessment corresponding to level A evidence is common practice in North America. A regime such as this was not previously implemented at our department. We hypothesized, that ventilation and weaning time would be reduced by a respective protocol and that the quality of weaning would be sustainable improved. Th e objective of this study was to evaluate the implementation of a multidisciplinary (respiratory therapist, physician, nurse) standardized weaning and extubation regime.

Methods: Setting: 8-bed intensive care unit with intubated surgical, trauma and medical patients. Inclusion criteria: >48 h mechanical ventilation by tracheal tube. Exclusion criteria: neuromuscular disease, dysphagia, LTOT and home respiratory care. In this prospective study a historical control group (n = 20) was used as the comparison group: physician directed weaned without protocol. Standardized weaning in the intervention group (n = 20) was exclusively performed by using the developed protocol: including weaning-criteria, weaning-assessment, weaning-algorithm with a spontaneous breathing trial and extubation criteria.

Results: Our regime reduced total time of ventilation (median = 169.1 h vs. 89.9 h) and weaning time (median = 73.35 h vs. 20.43 h) signifi cantly (p = 0.00329 and p = 0.0004) in the intervention group. Th e use of prerequisite extubation criteria in the invention group reduced the rate of recent ventilation by 50%. Th e reduction of weaning and ventilation time is based on multidisciplinary protocolized weaning. Th e main diff erence in weaning algorithm (implementation of a spontaneous breathing trial and the reduced use of a "comfort ventilation mode") can be discussed as additional reasons for benefi t.

Conclusions: Despite the acknowledgement of methodical limitations of the study and the small sample size it can be assumed that a standardized, multidisciplinary weaning and extubation regime improves the weaning process by reducing weaning and ventilation time. Th e study results approach to the implementation of a multidisciplinary protocol into European weaning practice.

Lung cancer is one of the most common malignancies in humans both in terms of frequency and mortality. On average, 1 in 12 men and 1 in 15 women will be diagnosed with lung cancer during their life time in the US and Europe. Most lung cancers are due to sporadic mutations in single cells and are strongly infl uenced by risk factors such as smoking or pollution. However, most of these preneoplastic cells are quiescent and do not progress to form overt tumors. It has been proposed that oncogenic stress activates the DNA damage response and the key tumor suppressor p53, which prohibits tumor growth. However, the molecular pathways by which cells sense a premalignant state in vivo are largely unknown. We found that the MKK7-JNK stress signaling pathway serves this vital function and show that lungspecifi c inactivation of MKK7 in a KRas(G12D)-driven NSLCLC mouse model markedly accelerates tumor onset and reduces overall survival. Mechanistically, MKK7 acts through the kinases JNK1 and JNK2, and this signaling pathway directly couples oncogenic and genotoxic stress to the stability of p53 by specifi c phosphorylation events, which is required for cell cycle arrest and suppression of epithelial lung cancer. To test whether MKK7-JNK signaling is also perturbed in human primary lung tumors, we analyzed MKK7 in samples from human NSLCLC patients. Phosphorylation of MKK7 was upregulated in NSCLCs compared to surrounding healthy tissue indicating that this pathway is actively engaged during tumorigensis. Strikingly, tumors in which p53 was mutated (confi rmed by sequencing) showed even higher phosphorylation of MKK7 than did tumors harboring wildtype p53 indicating a deregulated response in more advanced, malignant tumors. Th us, MKK7 is activated in primary human lung tumors and such hyperactivation seems to depend on p53 status.Th ese results show that MKK7 functions as a major tumor suppressor in lung cancer and identify MKK7 as a vital molecular sensor to set a cellular anticancer barrier.

Quality of life after lung transplantation in patients with cystic fi brosis: a cross-sectional study B. Smeritschnig, P. Jaksch, A. Scheed, W. Klepetko Background: Over the last years lung transplantation (LuTX) has become an established procedure for treatment of patients with endstage pulmonary diseases. Th e aim of the present cross-sectional study was therefore to provide an overview on quality of life and life satisfaction in lung transplant patients with cystic fi brosis.

Methods: All German speaking lung transplant recipients with cystic fi brosis were given a set of questionnaires (n = 45, response rate 95%): St. George's Respiratory Questionnaire (SGRQ), SF-36, the Hospital Anxiety and Depression Scale (HADS-D) , a likert scale of actually as spheroid formation assays and videomicroscopy were performed to analyze cell growth, survival and migration. Th e eff ect on downstream signal transduction was assessed by immunoblotting with phosphorylation site-specifi c antibodies.

Results: Expression analysis revealed high levels of FGFR1 together with the ligands FGF2 qand FGF18 in all MPM cell lines investigated. Stimulation with FGF2 showed remarkably increased migration and signifi cant changes in morphology reminiscent of epithelial mesenchymal transition. Inhibition of FGFR1 by the specifi c small molecule kinase inhibitor PD166866 lead to decreased proliferation, survival, migration and spheroid formation in all cell lines tested. Adenoviral expression of dominant-negative FGFR1 further confi rmed these results. Combination of FGFR inhibition with chemotherapeutic agents (e.g. cisplatin, gemcitabine, trabectedine) increased cytotoxicity.

Conclusions: Our data suggest that FGFR signals contribute to proliferation, survival, migration and chemotherapy resistance of MPM cells and their inhibition should be further evaluated as a potential new treatment strategy in this devastating malignancy. Infl ammatory cells such as mast cells, T-lymphocytes and dendritic cells have been described in the perivascular lesions in PAH. Th e strong pro-infl ammatory agent endothelin-1 (ET-1) was shown to be upregulated in PAH patients. So far, ET-1 has been found to be released from dendritic cells and to be involved in autocrine cell survival regulatory loops. However, the chemotactic eff ect of ET-1 on dendritic cells has yet to be elucidated.

Dendritic cells were directly isolated from peripheral venous blood of healthy donors by Ficoll Density Gradient Separation. As a next step Magnetic Cell Sorting (MACS®) for myeloid and plasmacytoid dendritic cells was performed. For the chemotaxis assays 48-well Boyden Chambers were used, of which the lower and upper compartments were separated by 8 μM pore-sized cellulose nitrate fi lters.

Dendritic cells were let to migrate towards ET-1 [10 -6 -10 -12 M]. In order to specify receptor signalling, dendritic cells were pre-incubated for 30 min with BQ-123, a well established ETAR inhibitor and BQ-788, which is a known inhibitor of the ETBR, before migration assays towards ET-1 [10 -8 M] were performed; fMLP [10 -8 M] served as positive control. After 4 hours at 37 °C in humidifi ed atmosphere, fi lters were dehydrated, stained and fi xed. Cell migration was analysed microscopically.

For the fi rst time ET-1 was shown to induce dendritic cell migration, displaying [10 -8 M] to be most eff ective. Furthermore, the ETAR inhibitor BQ-123 was proven to inhibit dendritic cell migration most signifi cantly at 10 -6 -10 -8 M. To compare, the ETBR inhibitor BQ-788 blocked the chemotactic eff ect of ET-1 at a broader concentration range [10 -6 -10 -12 M].

Th us, we conclude that ET-1 is a chemoattractant for human dendritic cells despite their origin and that this eff ect is more effi ciently inhibited by ETBR blockage than that of ETAR, reinforcing ET-1 to be a good therapeutic strategy for targeting the infl ammatory component of PAH.

Background: Th e oral, selective phosphodiesterase 4 inhibitor rofl umilast improves lung function and reduces exacerbations in patients with severe-to-very severe chronic obstructive pulmonary disease (COPD) and improves lung function and other clinical outcomes in patients with moderate-to-severe COPD who are receiving concomitant long-acting inhaled bronchodilators. We analyzed data from two 12-month studies that investigated the eff ect of rofl umilast on the rate of moderate or severe exacerbations in patients with severe-to-very severe COPD. Our aim was to investigate whether the effect of rofl umilast is infl uenced by concomitant maintenance treatment with bronchodilators (long-acting beta2 agonist [LABA] or short-acting muscarinic antagonist [SAMA]) or by treatment with inhaled corticosteroid (ICS) prior to randomization.

Methods: M2-124 and M2-125 were identically designed, doubleblind, randomized studies. Patients with severe-to-very severe COPD associated with cough and sputum production (chronic bronchitis) and a history of exacerbations were randomly assigned to either roflumilast 500 μg once daily (n = 1537) or placebo once daily (n = 1554) for 12 months. Concomitant LABA and regular SAMA use were allowed in all groups, but ICS was discontinued at randomization.

Results: LABAs were used by 749 (49%) patients in the rofl umilast group and 793 (51%) patients in the placebo group in the pooled data set. Th e corresponding numbers for regular SAMA use were 537 (35%) and 569 (37%), respectively; 650 (42%) and 657 (42%), respectively, were treated with ICS prior to randomization. Th e change in exacerbation rate with rofl umilast vs placebo was -16.9% (95% confi dence interval [CI] -25, -8) in the overall population and was not infl uenced by LABA use, with changes in exacerbation rates of -20.7% (95% CI -31, -9) and -14.6% (95% CI -26, -1) in the subgroups of LABA users and non-LABA users, respectively. Th e corresponding changes in ex-abstracts ÖGP Jahrestagung 2011 wkw 17-18/2011 © Springer-Verlag A33 ÖGP Background: Hypoxia is known to play a role in chemoresistance and tumor progression and is frequently found in solid tumors. It is widely accepted that the hypoxia-inducible factor 1-alpha (HIF-1a) is a key-regulator of hypoxia-induced chemotherapy resistance but downstream mechanisms are not entirely known. We wanted to investigate if regulation of pro-or antiapoptotic proteins is involved in hypoxia-induced chemoresistance.

Methods: A 549 cells were treated with cisplatin under normoxia and hypoxia (1% O 2 ). Viability was assayed with electronic pulse area analysis (CASY®). Apoptosis was assessed via fl ow cytometry (PhiPhi-Lux®) and TUNEL-assay. Expression of HIF-1a was detected with western blot. Regulation of members of the BCL-2 family was assessed with qRT-PCR and verifi ed with western blot.

Results: Cisplatin induced concentration-dependent apoptosis in A549 cells (p < 0.001). Hypoxia almost completely abolished this eff ect (p < 0.001). Th ese results were confi rmed using the PhiPhiLux® assay and 32 μM cisplatin (62.1 ± 3.7% apoptosis rate in normoxia vs. 21.7 ± 1.2% in hypoxia; p = 0.0005). HIF-1a was upregulated in hypoxia time-dependently. Bax mRNA was signifi cantly downregulated in hypoxic A549 cells (p < 0.01) whereas the corresponding anti-apoptotic protein Bcl-2 was not regulated by hypoxia, which was verifi ed by western blot (Fig. 1) .

Conclusions: Cisplatin-resistance in hypoxic A549 cells is due to a direct inhibition of apoptosis and is associated with a down-regulation of Bax. 

Effi cacy of Rofl umilast when used with Concomitant ICS from the OPUS/RATIO Studies

Solitary fi brous tumors of the pleura: eight new cases and review of 360 cases in the literature

Solitary fi brous tumors of the pleura

Background: Bronchiolitis obliterans syndrome (BOS) remains the most important complication in long-term follow-up after lung transplantation (LUTX) and has signifi cant impact on graft survival. We aimed to identify risk factors for BOS in general and in addition for the early onset (≤2 years post LUTX) of BOS.Methods: All LUTX from 1999 to 2009 and a survival of more than 6 months were retrospectively analyzed (n = 605). Patients with at least BOS 1(n = 151) were divided in 2 groups: A = onset of BOS ≤2 years post LUTX (n = 81); B = onset of BOS after 2 years (n = 70). Control group C = patients without BOS (n = 454).Results: Risk factors for the development of BOS were: cyclosporine as fi rst line immunosuppression, compared to tacrolimus (p ≤ 0.01), aspergillus infection post LUTX (p = 0.015), CMV infection post LUTX (p ≤ 0.01), no induction therapy (p = 0.029) and acute rejection episodes in the fi rst year after LUTX (p ≤ 0.01). Patients with cystic fi brosis are developing BOS less common (p ≤ 0.01) and later (p = 0.034) than patients with other diagnoses. Additional risk factors for an early onset of BOS were: aspergillus infection post LUTX (p ≤ 0.01), age (group A: 48.5 ± 12.9; B: 44.1 ± 14.5; p = 0.041) and lymphocytic bronchitis (p ≤ 0.01). 5-year graft survival from patients with BOS (52.1%) was signifi cantly lower (log rank ≤ 0.01) compared to patients without BOS (77.8%) and signifi cantly lower (log rank ≤ 0.01) in group A (26.0%) compared to group B (77.9%) as well.Conclusions: Cyclosporine as fi rst line immunosuppression, infections with CMV and aspergillus and acute rejections are potential risk factors for the development of BOS. Patients with higher age and lymphocytic bronchitis are at risk for an early onset of BOS and should be observed frequently.

Inhibition of the fi broblast growth factor receptor axis in malignant pleural mesothelioma: potential therapeutic implications Background: Th e increased amount of free-circulating DNA is present in blood of non-small cell lung cancer (NSCLC) patients, most likely due to up-regulated cell death processes. We believe that dynamics of plasma DNA changes monitored throughout treatment and follow-up period might prove useful for assessment of therapy eff ectiveness in NSCLC.Methods: We analyzed plasma DNA concentrations in 50 NSCLC patients prior and following the radical treatment (stage I-IIIA) or chemotherapy (IIIB), using qPCR method. In order to determine a potential contribution of chronic respiratory infl ammation to this phenomenon the levels of plasma DNA were analyzed in 30 COPD, 30 sarcoidosis and 30 persistent asthma patients as well.Results: Only resectable NSCLC (12.1 ng/ml), but not advanced NSCLC (4.4 ng/ml) group, showed signifi cantly higher mean plasma DNA concentration with respect to patients with chronic respiratory infl ammation (3.9 ng/ml) and 30 healthy controls (2.8 ng/ml; p < 0.001). Furthermore, a drastic increase in plasma DNA levels up to mean 68.74 ng/ml was observed a week after primary tumor resection or 24/48 hours after chemotherapy administration (16.4 ng/ml). Most resected NSCLC patients with no disease recurrence during 6-12 month follow-up demonstrated reduced plasma DNA levels (2.4 ng/ ml) with respect to their presurgical values. Conclusions: Increased plasma DNA level in NSCLC patients is due to the cancer but not chronic infl ammatory process. Drastic raise in plasma DNA levels observed after radical therapy are most likely due to the surgical trauma. Importantly, a trend towards reduction of free-circulating DNA concentration was observed in relapse-free patients. Th e eff ect of chemotherapy on plasma DNA in NSCLC IIIB patients is currently analyzed.

Iron defi ciency in non-anemic patients with chronic obstructive pulmonary disease Background: Iron defi ciency contributes to reduced exercise capacity in patients with heart failure. Th e repletion of iron improves cognitive, symptomatic, and exercise performance in these patients independent of hemoglobin. COPD shares many functional features of heart failure. Th us iron defi ciency could be a potential therapeutic target in COPD.Objectives: Th e aim of this study was to determine the prevalence of iron defi ciency in non-anemic patients with COPD. QOL (0%-100%), and a self-report questionnaire concerning social data, daily activities and adverse eff ects of immunosuppression.Results: Social data about professional life illustrate that after LuTX 49% are employed and 33% in retirement. 75% of the patients are married or in a common law marriage, 16% are living alone and 9% living still with parents. Most of all (98%) are able to do daily activities without problems and exercise diff erent sports regularly like fi tness training (47%), cycling (43%), swimming and so on. Adverse eff ects of immunosuppression, however turned out to be a important factor infl uencing LuTX recipients life quality: 19% suff er in a moderate to severe way of adverse eff ects. 77% have diabetes, 53% hypertension and 63% osteoporosis. However 93% are highly satisfi ed with the transplant outcome and 98% would opt for the procedure again.With regard to the SGRQ the LuTX recipients show signifi cantly better scores, equalling an increased quality of life, compared to the reference value of patients with obstructive pulmonary disease. HADS-D as well as SF-36 did not diff er signifi cantly to the published norms at healthy population. At last the actually QOL-scale shows 83 ± 17%.Conclusions: Although lung transplant patients have to cope with adverse eff ects of immunosuppression they report a highly satisfying quality of life. Th is is refl ected in the daily activities, regularly sports, retirement and the psychosocial situation. Methods: Between 2008 and 2010 data were analyzed from patients who have been assigned to our pretransplant clinic. Th e aim of the study was to determine the number of accepted, declined or postponed patients. Further we wanted to assess the number of listed patients, waiting list, diagnoses, waiting time, mortality and the frequency of high urgency reports.Results: In a period between 2008 and 2010 744 patients were examined and 981 conversations were conducted with these patients. After additional examinations 20% of the patients were refused and 47% were put on the waiting list. 33% were either in evaluation or had to optimize the clinical status (BMI, rehabilitation, muscular status). Th ese patients were postponed to further examination. In this period 498 patients were put on the waiting list with following diagnoses: COPD 31%, CF 21%, IPF 18%, IPH 8%, A1ATM 6% and re-TX with 6%. Waiting time depends always on urgency, blood group, height and diagnosis. Th e shortest waiting time had patients with IPH and CF, then IPF. Stable COPD-patients had the longest waiting period. Th e mortality on the waiting list is stable at the percentage rate of 6% over the years. Death on the waiting list depends on the diagnosis: re-TX 24%, IPF 19%, IPH 17%, CF 10% and at least COPD with 2%. In the period of 2008 to 2010 63 patients were listed with high urgency status primarily patients with CF, IPH and IPF. 51 were transplanted, 7 died before transplantation.Conclusions: Patients with IPF, IPH and CF have the highest mortality on the waiting list or have to be transplanted from the intensive care unit (HU-status). Patients with these diagnoses should be evaluated and listed earlier. Background: Patients with chronic obstructive pulmonary disease (COPD) are at an increased cardiovascular risk; however, the underlying mechanisms for this relationship are ill defi ned. Altered glucose metabolism may increase cardiovascular risk via impaired endothelial function. We conducted a longitudinal study to assess the interrelationship between systemic vascular function, glucose metabolism, and lung function in patients with COPD.Methods: 18 non-smoking patients with stable moderate to severe COPD (67% male; median [1st to 3rd quartiles] FEV1 % predicted 38% [28-55%]; body mass index 26 kg/m 2 [24-28 kg/m 2 ]) free from cardiovascular risk factors were studied. Systemic vascular function was assessed by means of fl ow mediated dilation technique of the brachial artery. Laboratory measurements included fasting blood glucose levels, circulating concentrations of insulin, C-reactive protein, and fibrinogen. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was determined. Measurements were performed at baseline and were repeated after twelve months.Results: Flow-mediated dilation signifi cantly decreased from 13.5% [11-15%] at baseline to 9.8% Conclusions: Altered glucose metabolism may be associated with progression of endothelial dysfunction and thus increased cardiovascular risk in patients with COPD.

Asthma treatment with beclomethasone/formoterol: disease control and patient-reported outcomes Background: To evaluate data regarding asthma control, tolerability and compliance with beclomethasone/formoterol (Foster ® ) under real-life conditions, a prospective, multicenter, non-interventional study (NIS) was conducted in pneumologic and general practices all over Austria in 2010.Methods: Treatment consisted of 100 μg extra-fi ne beclomethasone/6 μg formoterol (BDP/F) of 1-2 inhalations twice daily over a 12-week period. Overall 237 patients were enrolled. Asthma control was examined before and after the observation period corresponding to a 3-point scale (controlled/partly controlled/non controlled). Pulmonary function (PEF, FEV 1 , FVC) was measured at the beginning, in week 4-8 and 12 of the therapy. Th e number of asthma attacks (day and night time) as well as the severity of asthma Methods: Serum markers of iron status were measured in 53 stable non-anemic (hemoglobin > 12 g/l) COPD patients (53% males; mean age 64 ± 8 years, mean FEV1 predicted 41 ± 18%; GOLD stage II, III, and IV was 34%, 32%, and 34%, respectively). Iron defi ciency was diagnosed when the serum ferritin level was either <100 μg/l or was between 100 and 299 μg/l with the transferrin saturation <20%.Results: Th e serum ferritin level was <100 μg/l in 20 patients. Th e serum ferritin level was between 100 and 299 μg/l and transferrin saturation was <20% in 6 patients. Th us iron defi ciency was present in 49% of the patients. Th e median soluble transferrin receptor to log_ ferritin ratio was higher in patients with iron defi ciency (1.7, 1.0 to 1.4) compared to patients without (1.7, 1.4 to 2.0), p < 0.001.Conclusions: Iron defi ciency is present in half of the patients with stable COPD. A randomized, placebo-controlled trial should clarify whether repletion of iron stores improves functional performance in COPD patients with iron defi ciency. Background: Patients with COPD are at an increased risk of cardiovascular morbidity and mortality, however, the underlying mechanisms remain poorly defi ned. Th e present study investigated early markers of cardiovascular disease in patients with COPD and controls.Methods: Th e study sample consisted of 60 patients with stable COPD (mean ± SD age 64 ± 8 yrs, FEV1 41 ± 18% predicted, BMI 24 ± 4 kg/sqm) and 20 age, gender, and body-weight matched controls without airfl ow obstruction. Both patients and controls were free from traditional cardiovascular risk factors including hypertension, diabetes, or hyperlipidemia. Study participants underwent measurements of brachial artery intima-media thickness (bIMT) and circulating levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA).Results: bIMT was signifi cantly higher in patients with COPD than controls (0.37 ± 0.08 mm vs. 0.32 ± 0.06 mm; p = 0.007). Th ere was a signifi cant inverse relationship between bIMT and FEV1% predicted (r = -0.304; p < 0.002) within the complete study sample. We observed no signifi cant diff erences in lnADMA levels between patients with COPD and controls (-0.68 ± 0.30 μmol/l vs. -0.57 ± 0.18 μMol/l; p = 0.057). However there was a signifi cant positive relationship between bIMT and lnADMA levels in patients with COPD (r = 0.331; p = 0.013).Conclusions: Th is study provides evidence of both structural and biochemical characteristics of subclinical atherosclerosis in patients with COPD. abstracts A32 ÖGP acerbation rates for concomitant SAMA use vs non-SAMA use were -13.1% (95% CI -24, -1) and -19.8% (95% CI -30, -8), respectively. In patients with and without prior ICS treatment, exacerbations changed by -19.3% (95% CI -30, -7) and -16.8% (95% CI -28, -4), respectively, with rofl umilast vs placebo.Conclusions: In two 12-month studies, rofl umilast reduced the frequency of moderate and severe exacerbations independent of concomitant maintenance bronchodilator treatment (LABA or SAMA), or treatment with ICS prior to randomization.

Triple Endoscopy (TRES) with fl exible bronchoscopesfeasible or not feasible W. Weinwurm, R. Kropfmüller, W. Duller, H. Schinko

Background: Triple or panendoscopy evaluates larynx, trachea and proximal oesophagus in cancer of the larynx and thyroid gland. Trachea, mainstem bronchi, and esophagus lay next to each other and so do their cancers, causing stenosis. EBUS can be used for transesophageal fi ne needle aspirations as well. GER is associated with chronic cough and explored by esophago-gastroscopy (OGD). Even the stomach is in the reach of fl exible bronchoscopes.Aim of the study: Lack of information about simultaneous broncho-esophagoscopy let us explore the feasibility and (dis)advantages of TRES using fl exible bronchoscopes.Methods: Olympus bronchoscopes were used for TRES in 16 patients (7 F, 9 M -age mean ± 2SD 66 ± 13 years). Bronchoscopy was immediately followed by esophago-gastric inspection under local anaesthesia via nasal or oral route.Results: 17 broncho-esophago-gastroscopies (TRES) were carried out with the same bronchoscope adjusted by an inserted catheter for insuffl ation of pressurized air. No adverse event occurred.

Hyperinfl ation associated with COPD is associated with impaired cardiac function and spontaneous baroreceptor sensitivity Background: Th ere is evidence of impaired biventricular preload associated with hyperinfl ation in patients with COPD. A reduction in cardiac fi lling pressures may result in unloading of baroreceptors. We therefore investigated baroreceptor sensitivity, an independent predictor of cardiovascular morbidity and mortality, in patients with COPD and controls.Methods: 25 patients with COPD free from clinical cardiovascular disease (age 58 ± 7yrs, FEV1 28 ± 7%, TLC 137 ± 20%) and 12 age, gender, and body-weight matched controls without airfl ow obstruction were studied. Participants underwent comprehensive hemodynamic measurements and assessment of arterial barorefl ex modulation of heart rate during resting conditions and mental stress testing.Results: Patients with COPD had signifi cantly lower stroke index (p < 0.001), however, signifi cantly higher heart rate (p < 0.001) and higher total peripheral resistance compared with controls (p = 0.05). Th e mean slope of spontaneous baroreceptor sequences was significantly lower in patients with COPD than controls during both resting conditions (p < 0.01) and mental stress testing (p = 0.03). Th ere was a symptoms (dyspnoea, wheezing, rapid breathing and cough) and exacerbations were assessed. In addition a patient-check (GINA Guidelines 2009) was performed to gain important asthmarelevant data.Results: After 12-week treatment with BDP/F 81.4% of patient population showed good asthma control. Signifi cant improvement in pulmonary function (PEF, FEV 1 , FVC) was observed in all patients. Th e number of asthma attacks was reduced from 1.3 weekly to 0.1 weekly at day time (1.0 to 0.1 weekly at night time). Th e median severity of observed asthma symptoms as well as exacerbations decreased, latter with the main improvement within the fi rst weeks of treatment. All results which were collected with the patient-check showed a signifi cant improvement all over the 12 treatment weeks. Worth to be mentioned is the signifi cant decrease of the nocturnal awakening (65% to 10.2%; p > 0.01) under BDP/F. No adverse eff ects were reported during the whole observation period.Conclusions: Th e results of this NIS show that Beclomethasone/ Formoterol fi xcombination enhances eff ectively patients' asthma control by decreasing asthma attacks, symptoms and exacerbations and by improving lung function (PEF, FEV 1 , FVC) and patient reported outcomes.

Effi cacy of rofl umilast in patients receiving concomitant treatments for chronic obstructive pulmonary disease over 12 months R. Voves 1 , W. Pohl 2 , H. Jamnig 3 , C. Schmid-Wirlitsch 4 , I. Moll-Schüler 5 , N. A. Hanania 6 tions. Th is post-hoc analysis studied the eff ects of rofl umilast vs placebo in COPD patients with or without concomitant ICS treatment. Methods: Th is pooled, post-hoc analysis of two replicate, randomized, double-blind, placebo-controlled studies (M2-111 and M2-112) compared oral rofl umilast 500 μg QD with placebo over 52 weeks. Stable dose ICS use was permitted. Lung function outcomes and exacerbation rates were examined.Results: Of 2686 randomized patients, 1622 used concomitant ICS (n = 809 rofl umilast and n = 813 placebo) and 1064 did not (n = 518 and n = 546, respectively). Among patients receiving concomitant ICS, 65% signifi cant relationship between stroke index with FEV1% predicted (r = 0.588, p < 0.001), total lung capacity (r = -0.391, p = 0.01) and RV/ TLC ratio (r = -0.491, p = 0.002). Similar associations were observed between baroreceptor sensitivity and markers of airfl ow obstruction and hyperinfl ation.Conclusions: Impaired cardiac fi lling in patients with COPD may be related to hyperinfl ation. Our fi ndings furthermore indicate a link between baroreceptor function and increased lung volumes in COPD. Methods: 13 patients with lymphocytic exudates (10 pleural, 2 ascites, 1 joint fl uid) suspicious for TB were prospectively studied. Flow cytometry for intracellular detection of IFN-γ in CD4 + T cells as well as surface receptor staining (CD27, CCR and CD45RO) were performed after overnight stimulation of mononuclear cells from peripheral blood and the site of disease with early secretory antigenic target (ESAT)-6.

Results: In 6 patients active TB was confi rmed. As expected, TB patients were shown to enrich MTB-specifi c, IFN-γ expressing CD4 + T cells at the site of infection when compared to blood (p < 0.05). No enrichment of MTB-specifi c T cells was found in the 7 patients with non-TB disease. Both CD27 and CCR7 signifi cantly decreased on CD4 + T cells in TB patients (CD27, median: blood 94.1%, site of infection 63.6%; CCR7, median: blood 79.9%, site of infection 43.9%; p < 0.05, respectively). Th is fi nding was even more striking within the memory (CD4 + /CD45RO + ) subset. In contrast, in the non-TB group even an increase of CD27 on the CD4 + and CD4 + /CD45RO + subset in the exudates was noted (p < 0.05).Conclusions: Active TB can not only be diagnosed by the enumeration of MTB-specifi c, IFN-γ expressing T cells at the site of infectionadditional signatures such as the decrease of T cell associated CD27 and CCR7 hold promise as new markers for immune-diagnosis of TB.

Down-regulation of the pro-apoptotic BCL-2 family member protein Bax by hypoxia may contribute to hypoxia-induced chemotherapy resistance in A549 lung cancer cells* Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and late possible consequence of venous thromboembolism. Th e fi rst pathogenic components of CTEPH are the primary obstruction of the central pulmonary arteries by accumulation of thrombotic material and the second is severe pulmonary vascular remodeling. In the surgical tissue from CTEPH patients, the formation of vessels is often detected. How these vessels are formed and from which cell source, however is not well known yet. A bacterial infection might be a major determinant of thrombosis, fi brosis and the remodelling events, where chemokines might play a critical role in angiogenesis.Our aim was to check the presence of infl ammatory markers and receptors, which play a role in promoting angiogenesis in the PEA material and their receptors, elucidating the mechanism of angiogenesis in CTEPH clots.Methods: Flow-cytometric analysis: Th e PEA samples were put in endothelial cell basal medium supplemented with 5% FCS and antibiotics. Th e tissue was cut into small pieces and incubated for 18h at 37°C. Th e supernatant was collected and stored at -20°C; afterwards the tissue was briefl y washed with Hepes buff er and lysed in 150 μl RIPA buff er with PhosphoStop and Protease Inhibitor Complex. Th e supernatant and the lysate were checked for infl ammatory factors such as IL-8, RANTES, MIG, MCP-1, IP-10, IL-2, IL-4, IL-6, IL-10, TNF, IFN-g (Human Chemokine and Th 1/Th 2 Cytokine Kit).Immunohistochemistry: Th e PEA material was fi xed in 3% formaldehyde for 24 h and embedded in paraffi n blocks. Immunohistochemistry was performed on the 2 μm thick sliced paraffi n tissue using primary antibodies for von Willebrand factor (Dako), or smα-Actin (Sigma) and goat-anti-rabbit-HRP secondary antibodies (Santa Cruz Biotechnologies) or goat-anti-mouse-HRP (Santa Cruz Biotechnologies) for double staining. Results: In the CTEPH surgical material the presence of infl ammatory markers such as IL6; IL8 and MCP-I were found. Beside these chemokines, their receptors were also present in the PEA tissue. Vessels formed in the CTEPH clots were detected and stained for vWF, smooth muscle alpha-actin and CD31.Conclusions: IL8 and its receptor are known to play a role in angiogenesis and chemotaxis, therefore it might attract the endothelial cells to the occluded region of the pulmonary artery.had severe disease vs 68% without ICS; 28% with ICS vs 21% without ICS had very severe COPD. For the overall population, pre-bronchodilator and post-bronchodilator FEV1 improved (mean ± SE) with rofl umilast compared to placebo by 51 ± 7 mL (p < 0.0001) and 53 ± 8 mL (p < 0.0001) and exacerbations were decreased by 14.3% (p = 0.026). With concomitant ICS use, pre-bronchodilator FEV1 (53 ± 9 mL; p < 0.0001) and post-bronchodilator FEV1 (54 ± 9 mL; p < 0.0001) improved with rofl umilast vs placebo. Without concomitant ICS use, pre-bronchodilator FEV1 (49 ± 13 mL; p = 0.0002) and post-bronchodilator FEV1 (53 ± 13 mL; p < 0.0001) improved with rofl umilast compared to placebo. Rofl umilast + ICS reduced the moderate/severe exacerbation rate vs placebo + ICS (rate ratio 0.72 vs 0.89; -18.8%; p = 0.014); the percentage of patients experiencing an exacerbation was numerically lower with rofl umilast + ICS vs placebo + ICS (36% vs 42%). Without concomitant ICS, the exacerbation rate (rofl umilast 0.42; placebo 0.46; -7.7%; p = 0.55) was not aff ected by rofl umilast; the percentage of patients experiencing an exacerbation was numerically lower with rofl umilast vs placebo (23% vs 27%).Conclusions: Rofl umilast was eff ective at improving lung function independent of concomitant ICS use and reduced exacerbation rates in patients taking concomitant ICS, who may be recognized by clinicians as more likely to experience exacerbations. Rofl umilast improves lung function, reduces the rate of exacerbations, and can have an additive eff ect in patients receiving concomitant ICS.

High chemokine levels are present in PEA tissue of CTEPH patients D. Zabini 1 , Z. Bálint 2 , A. Heinemann 3 , P. Nierlich 4 , I. Lang 5 , A. Olschewski 1,2